PCN151 - COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB IN THE TREATMENT OF PATIENTS WITH HEPATOCELULLAR CARCINOMA PREVIOUSLY TREATED WITH SORAFENIB IN PORTUGAL (English)
- New search for: André, S.
- New search for: Graça, A.
- New search for: Soares, V.
- New search for: André, S.
- New search for: Graça, A.
- New search for: Soares, V.
In:
Value in health
;
21
, 3
;
S40
;
2018
-
ISSN:
- Article (Journal) / Print
-
Title:PCN151 - COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB IN THE TREATMENT OF PATIENTS WITH HEPATOCELULLAR CARCINOMA PREVIOUSLY TREATED WITH SORAFENIB IN PORTUGAL
-
Contributors:
-
Published in:Value in health ; 21, 3 ; S40
-
Publisher:
- New search for: Elsevier Science B.V., Amsterdam
-
Publication date:2018-01-01
-
Size:S40
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 610.28
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 610.28 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 21, Issue 3
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 249
-
Affordability of New Technologies: The Next FrontierTowse, Adrian / Mauskopf, Josephine A. et al. | 2018
- 252
-
Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and CuresDanzon, Patricia M. et al. | 2018
- 258
-
The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care ValuePearson, Steven D. et al. | 2018
- 266
-
Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget ImpactsLomas, James / Claxton, Karl / Martin, Stephen / Soares, Marta et al. | 2018
- 276
-
Paying for Cures: Perspectives on Solutions to the "Affordability Issue"Schaffer, Sarah Karlsberg / Messner, Donna / Mestre-Ferrandiz, Jorge / Tambor, Ellen / Towse, Adrian et al. | 2018
- 280
-
Affordability of Health Care: A Global CrisisWatkins, John B. et al. | 2018
- 283
-
Estimating the Learning Curve of a Novel Medical Device: Bipolar Sealer Use in Unilateral Total Knee ArthroplastiesKuznietsova, Victoria / Woodward, Robert S. et al. | 2018
- 295
-
Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational StudyRapp, Thomas / Andrieu, Sandrine / Chartier, Florence / Deberdt, Walter / Reed, Catherine / Belger, Mark / Vellas, Bruno et al. | 2018
- 304
-
Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer PatientsZhong, Yue / Valderrama, Adriana / Yao, Jianying / Donga, Prina / Bilir, Pinar / Neumann, Peter J. et al. | 2018
- 310
-
Cost-Effectiveness of Antibiotic Prophylaxis Strategies for Transrectal Prostate Biopsy in an Era of Increasing Antimicrobial ResistanceLee, Kyueun / Drekonja, Dimitri M. / Enns, Eva A. et al. | 2018
- 318
-
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney DiseaseHabbous, Steven / Przech, Sebastian / Martin, Janet / Garg, Amit X. / Sarma, Sisira et al. | 2018
- 326
-
Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?Malone, Daniel C. / Brown, Mary / Hurwitz, Jason T. / Peters, Loretta / Graff, Jennifer S. et al. | 2018
- 334
-
Sensitivity of Claims-Based Algorithms to Ascertain Smoking Status More Than Doubled with Meaningful UseHuo, Jinhai / Yang, Ming / Tina Shih, Ya-Chen et al. | 2018
- 341
-
What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10, 000/QALY?Carroll, Christopher / Houten, Rachel / Boland, Angela / Kaltenthaler, Eva / Dickson, Rumona et al. | 2018
- 351
-
The Importance of Model Structure in the Cost-Effectiveness Analysis of Primary Care Interventions for the Management of HypertensionPeñaloza-Ramos, Maria Cristina / Jowett, Sue / Sutton, Andrew John / McManus, Richard J. / Barton, Pelham et al. | 2018
- 364
-
Associations of Smoking, Physical Inactivity, Heavy Drinking, and Obesity with Quality-Adjusted Life Expectancy among US Adults with DepressionJia, Haomiao / Zack, Matthew M. / Gottesman, Irving I. / Thompson, William W. et al. | 2018
- i
-
Table of Contents| 2018
- S2
-
CE1 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALSRamos, M. / Foos, V. / Ustyugova, A.V. / Hau, N. / Gandhi, P. / Lamotte, M. et al. | 2018
- S3
-
CN2 - PREDICTING UTILITY SCORES IN LOCALIZED PROSTATE CANCER: MAPPING FROM EPIC TO PORPUSZamora, V. / À, Pont / Garin, O. / Pardo, Y. / Ferrer Fores, M. et al. | 2018
- S4
-
CN6 - COST-EFFECTIVENESS MODEL OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE (FLT3+) ACUTE MYELOID LEUKEMIA (AML): A FRENCH PERSPECTIVECariou, C. / Tremblay, G. / Dolph, M. / Brandt, P.S. / Forsythe, A. et al. | 2018
- S5
-
CP4 - WEIGHTED AVERAGE CALCULATIONS FOR POPULATING COST-EFFECTIVENESS MODELS: HOW IGNORING THE MODEL'S CLINICAL PATHWAYS CAN SIGNIFICANTLY BIAS THE INCREMENTAL COST-EFFECTIVENESS RATIO (ICER)Van Vlaenderen, I. / Moeremans, K. / Van Bellinghen, L. et al. | 2018
- S6
-
DB1 - GLYCAEMIC CONTROL, CARDIOVASCULAR DISEASE AND MORTALITY IN TYPE 2 DIABETES (T2D) PATIENTS IN A REAL LIFE SETTING OVER TIME: POPULATION-BASED DATA FROM THE NETHERLANDSHouben, E. / Heintjes, E. / Cremers, S. / Beekman, W. / Beest F, Penning-van / Stehouwer, C. / Herings, R. et al. | 2018
- S8
-
HT3 - DESCRIPTION AND COMPARISON OF EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENTPisarczyk, K. / Hajjeji, B. / Rémuzat, C. / Espín, J. / Toumi, M. et al. | 2018
- S9
-
HT8 - DOES IQWIG MATTER? FREQUENCY OF DIVERGENT OPINIONS BETWEEN IQWIG AND THE G-BAMacaulay, R. / Mohamoud, Z. / Schmidt, B. et al. | 2018
- S10
-
MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA: INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMABlommestein, H. / van Beurden-Tan, C. / de Groot, S. / Blijlevens, N. / Sonneveld, P. / Groot CA, Uyl-de / Zweegman, S. / Franken, M.G. et al. | 2018
- S11
-
ND2 - FUNCTIONAL LOSS ACROSS STAGES OF ALZHEIMER'STsong, W. / Jones, E. / Pike, J. / Bluff, D. et al. | 2018
- S12
-
PP4 - ONE SIZE DOES NOT FIT ALL: HETEROGENEOUS PATIENT PREFERENCES AND TRADEOFFS FOR ANTIRETROVIRAL THERAPY - RESULTS OF A DISCRETE CHOICE EXPERIMENTOstermann, J. / Derrick, C. / Yelverton, V. / Hobbie, A. / Weinhold, A. / Thielman, N. et al. | 2018
- S15
-
PCN5 - TREATMENTS OF RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER IN ROUTINE CLINICAL PRACTICE – A SYSTEMATIC REVIEWBhutani, M.K. / Rajora, P. / Soni, D. / Pan, J.J. et al. | 2018
- S16
-
PCN10 - ECONOMIC IMPACT OF MEDICATION ERRORS DETECTED IN ONCOLOGIC INPATIENTS AND OUTPATIENTS IN A MEXICAN HOSPITALMorales Perez, M. / Paladio-Hernandez, J.A. / Luna Mendoza, D. / Paredes-Garcia, P. / Munguia Juarez, L. / Sanchez Rodriguez, I. / Lopez-Luis, J. / Hernandez-Martinez, J. / Ramirez-Padilla, L. / Diaz-Rosales, S. et al. | 2018
- S17
-
PCN17 - INDIRECT TREATMENT COMPARISONS OF NIVOLUMAB VERSUS REGORAFENIB, CABOZANTINIB AND BEST SUPPORTIVE CARE AFTER TREATMENT WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMARoskell, N. / Gregory, J. / Wisniewski, T. / Thompson, G.J. / De la Cruz, C. et al. | 2018
- S18
-
PCN23 - EFFICIENCY OF NIVOLUMAB TREATMENT AFTER PLATINUM CHEMOTHERAPY IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN SPAINSuarez, J. / Juarez-Garcia, A. / Shaw, J.W. / Contente, M. / Polanco, C. et al. | 2018
- S19
-
PCN30 - EVIDENCE GENERATION IN A EARLY ACCESS STRATEGY FOR TARGETED ONCOLOGY THERAPIES: A COMPARISON IN NON-SMALL CELL LUNG CANCERvan Hooijdonk, I.E. / Lai, L. / van Engen, A. et al. | 2018
- S20
-
PCN37 - MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF APALUTAMIDE AND ENZALUTAMIDE IN THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCERChowdhury, S. / Oudard, S. / Hadaschik, B.A. / Uemura, H. / Joniau, S. / Pilon, D. / Ladouceur, M. / Behl, A. / Liu, J. / Dearden, L. et al. | 2018
- S21
-
PCN43 - A TARGETED REVIEW OF NICE SINGLE TECHNOLOGY APPRAISALS (STAS) IN UROTHELIAL CANCER SINCE THE INTRODUCTION OF THE NEW CANCER DRUGS FUND (CDF)Adedokun, L. / Penaloza-Ramos, C. / Lee, J. et al. | 2018
- S22
-
PCN53 - STRUCTURED LITERATURE REVIEW OF THE PREVALENCE OF MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORSLorenzi, M. / Amonkar, M. / Zhang, J. / Mehta, S. / Liaw, K. et al. | 2018
- S23
-
PCN58 - MEDIAN SURVIVAL, MEAN SURVIVAL OR HAZARD RATIO: WHICH ENDPOINT IS THE MOST APPROPRIATE FOR PATIENTS, PHYSICIANS AND POLICY MAKERS?Ben-Aharon, O. / Magnezi, R. / Leshno, M. / Goldstein, D.A. et al. | 2018
- S25
-
PCN70 - ASSESSING THE BUDGET IMPACT OF INCLUDING SUNITINIB FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ARGENTINAMacmullen, M. et al. | 2018
- S26
-
PCN75 - BUDGET IMPACT MODEL OF SUBCUTANEOUS TRASTUZUMAB COMPARED WITH INTRAVENOUS TRASTUZUMAB ON THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEMKashiura, D. / Souza, P.V. / Garrido, S.D. / Nardi, E. / Alves, M. et al. | 2018
- S27
-
PCN80 - BUDGET IMPACT ANALYSIS WITH USE OF SUBCUTANEUS TRASTUZUMABPoquet-Jornet, J.E. / Carrera Hueso, J. / Crespo, C. / Cuesta-Grueso, C. / Ramón Barrios, M.A. / Gasent-Blesa, J.M. / Fortuny-Organs, B. et al. | 2018
- S30
-
PCN96 - INITIAL THERAPY FOR ADVANCED PROSTATE CARCINOMA (PCA) WITH A GNRH AGONIST (GNRHA) AND ANTAGONISTS - A RETROSPECTIVE ANALYSIS OF PRESCRIPTION PATTERNS AND HOSPITAL COSTS BASED ON GERMAN GKV [GESETZLICHE KRANKENVERSICHERUNG (STATUTORY HEALTH INSURANCE)] DATAHupe, M.C. / Hammerer, P. / Ketz, M. / Kossack, N. / Colling, C. / Merseburger, A.S. et al. | 2018
- S31
-
PCN103 - PREDICTED TREATMENT COSTS AND SAVINGS PER PATIENT OF KANJINTI® (TRASTUZUMAB BIOSIMILAR) VS. SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) HERCEPTIN® AND OTHER TRASTUZUMAB BIOSIMILARS IN ITALYAgirrezabal, I. / Gaikwad, I. / Cirillo, L. / Lothgren, M. et al. | 2018
- S32
-
PCN108 - TARGETED LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN UROTHELIAL CARCINOMAShah, M.V. / McGovern, A. / Hepp, Z. et al. | 2018
- S34
-
PCN121 - BSC COST IN TERMINAL CANCER PATIENTS IN KOREAPark, M. et al. | 2018
- S37
-
PCN138 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER IN ENGLANDTsoumani, E. / D'Oca, K. / Zhong, Y. / Prabhu, V.S. / Xu, R. / Li, H. et al. | 2018
- S38
-
PCN143 - HEALTH ECONOMIC EVALUATION OF BIOLOGIC AGENTS FOR METASTATIC COLORECTAL CANCER PATIENTS IN BRAZILCarvalho, A.C. / Cao, Q. / van Asselt, A. / Sasse, A.D. / Postma, M.J. et al. | 2018
- S39
-
PCN148 - COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB COMPARED TO TREATMENT OPTIONS FOR ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER PRIOR CHEMOTHERAPY - UPDATED RESULTSKourkoulas, N. / Athanasakis, K. / Kakouros, M. / Skroumpelos, A. / Kyriopoulos, J. et al. | 2018
- S40
-
PCN153 - COST-EFFECTIVENESS ANALYSIS OF APALUTAMIDE FOR TREATMENT IN NON- METASTASIS CASTRATION-RESISTANT PROSTATE CANCERZhou, Z. / Hu, X. et al. | 2018
- S41
-
PCN163 - COST-EFFECTIVENESS OF ADD-ON PERTUZUMAB COMBINED WITH TRASTUZUMAB AND DOCETAXEL VERSUS PLACEBO AS TREATMENT OF HER-2 POSITIVE METASTATIC BREAST CANCER IN CZECH REPUBLICDoležel, J. / Pour, M. / Skalický, D. / Fínek, J. et al. | 2018
- S42
-
PCN169 - A FLEXIBLE OPEN-SOURCE COST-EFFECTIVENESS MODEL FOR METASTATIC EGFR+ NON-SMALL CELL LUNG CANCERJansen, J.P. / Incerti, D. / Shafrin, J. / Frederickson, A.M. / Lakdawalla, D.N. / Reckamp, K.L. et al. | 2018
- S43
-
PCN174 - NEPA, AN ORAL FIXED COMBINATION OF NETUPITANT AND PALONOSETRON, IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN GERMANY AND GREECEBourhis, F. / Eriksson, J. / Ruffo, P. / D'Agostino, P. / Turini, M. et al. | 2018
- S44
-
PCN179 - THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT ERYTHROPOIESIS-STIMULANTIG AGENTS FOR MANAGING CHEMOTHERAPY-INDUCED ANEMIA IN ADULT CANCER PATIENTS IN ACTUAL PRACTICE IN RUSSIAKrysanova, V. / Krysanov, I. / Ermakova, V. et al. | 2018
- S46
-
PCN192 - ROBOTIC VERSUS LAPAROSCOPIC DISTAL PANCREATECTOMY: A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS ANALYSISNuñez Alfonsel, J. / Ielpo, B. / Quijano, Y. / Vicente, E. / Hidalgo, A. et al. | 2018
- S47
-
PCN199 - HOW DO QUALITY-ADJUSTED LIFE YEARS IMPACT REIMBURSEMENT DECISION-MAKING IN THE UK?Farinella, M. / Rubinstein, J. / Inumerable, R.V. / Gizaw, N. / Ho, Y. et al. | 2018
- S48
-
PCN204 - A SYSTEMATIC REVIEW OF BARRIERS AND FACILITATORS TO PARTICIPATION IN SHARED DECISION MAKING IN CANCER CARE: AN INTERNATIONAL PERSPECTIVEKamal, K.M. / Covvey, J.R. / Mehta, Z. / Zacker, C. et al. | 2018
- S49
-
PCN210 - USING REAL WORLD DATA TO DETERMINE HEALTH SYSTEM COSTS OF A 5-YEAR NON-SMALL CELL LUNG CANCER COHORTSeung, S.J. / Hurry, M. / Walton, R.N. / Evans, W.K. et al. | 2018
- S50
-
PCN216 - CONTEMPORARY REAL-WORLD EVIDENCES ON ALK+ NSCLC PATIENTS IN ITALYTucci, C. / Trimarchi, C. / Urbinati, D. / Demma, F. / Fico, M. / Fioravanti, L. et al. | 2018
- S51
-
PCN221 - STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER TREATMENT PATTERNS AND COSTS: AN ONTARIO, CANADA ANALYSISSeung, S.J. / Hurry, M. / Walton, R.N. / Evans, W.K. et al. | 2018
- S52
-
PCN227 - ACCESS TO ESSENTIAL ANTINEOPLASTICS AND IMMUNOSUPPRESSIVESKazaryan, I. / Sevikyan, A. / Amirkhanyan, A. / Melikyan, M. et al. | 2018
- S53
-
PCN232 - VARIATION IN ACCESS TO PD-1 IMMUNOTHERAPIES IN EUROPELast, V. / Hickey, D.A. et al. | 2018
- S55
-
PCN245 - WHAT DRUGS SHOULD BE IN THE FOCUS OF COMPLEX EVALUATION IN PATIENTS WITH BREAST CANCER IN MOSCOWTolkushin, A. / Davydovskaya, M. / Ermolaeva, T. / Kokushkin, K. / Poliakova, K. et al. | 2018
- S56
-
PCN250 - ASSESSING THE REAL WORLD USAGE OF PD-1 INHIBITORS IN ADVANCED MELANOMA ACROSS EU5Rider, A. / Lewis, K. / Higson, O. et al. | 2018
- S58
-
PCN263 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH PROSTATE CANCER IN SPAIN.Solozabal, M. / De Prado, A. / Planellas, L. / Á, Baltasar-Sanchez / Carreño-Serra, A. / Callejo-Velasco, D. et al. | 2018
- S59
-
PCN268 - TREATMENTS AND HEALTH CARE UTILISATION (HCU) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) FOLLOWING INITIAL PLATINUM THERAPY IN THE UNITED KINGDOMParikh, R.C. / Kurosky, S. / Kaye, J.A. / Levine, C. / Hettle, R. / Shire, N. / Mann, H. / Wang, H. et al. | 2018
- S60
-
PCN274 - TIME TO PRICE CHANGE FOLLOWING HTA DECISIONSLiden, D. / Jao, R. / Adler, B.N. / Lockwood, C. / Reinaud, F. et al. | 2018
- S61
-
PCN280 - IMPACT OF SUBOPTIMAL CLINICAL EVIDENCE ON HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONSZou, D. / Desrosiers, N. / Wu, S. / Prawitz, T. / Tervonen, T. / Marsh, K. / Caro, J.J. et al. | 2018
- S62
-
PCN286 - INCREMENTAL COST-EFFECTIVENESS RATIO FOR THE ANTINEOPLASTIC DRUGS APPROVED AND REJECTED FOR THE VITAL AND ESSENTIAL DRUGS LIST IN 2017 IN RUSSIAOmelyanovskiy, V. / Avxentyeva, M. / Sura, M. / Savilova, A.G. / Khachatryan, G.R. et al. | 2018
- S63
-
PCN292 - CANCER DRUGS IN GERMANY: HTA DECISIONS OF NEW AND INNOVATIVE ONCOLOGY DRUGS IN GERMANY – AN ANALYSIS USING THE PRISMACCESS® DATABASEMayer, F. / Hodek, J. / Walzer, S. et al. | 2018
- S64
-
PCN298 - MANAGEMENT OF ANTIEMETIC TREATMENT FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV): PATIENTS', ONCOLOGISTS' AND NURSES' PERSPECTIVESDuracinsky, M. / Chassany, O. / Griffith, J. / Coblentz-Baumann, L. et al. | 2018
- S65
-
PCN303 - ASSESSING THE VALUE OF NOVEL IMMUNO-ONCOLOGY (I-O) THERAPIES: HOW CONSISTENT IS THE HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES' CONSIDERATION OF THE SURVIVAL BENEFIT IN THE ABSENCE OF LONG-TERM DATA?Jonsson, B. / Chao, D. / Toumi, M. / Child, A. / Morris, J. / Hertel, N. et al. | 2018
- S66
-
PCN310 - SURVIVAL IN CANCER CLINICAL TRIALS: A COMPARISON OF EMA APPROVALS AND NICE RECOMMENDATIONS.Filby, A. / Edwards, H.K. / Beggs, L. / O'Brien, S. et al. | 2018
- S67
-
PCN315 - IMPACT OF PRO DATA ON IQWIG BENEFIT RATINGS IN ONCOLOGYLie, X. / Kempf, L. / van Engen, A. et al. | 2018
- S68
-
PCN321 - COMPARISON OF RECOMMENDATIONS FOR CANCER DRUGS CARRIED OUT BY THREE HTA BODIES (2015-2018): NICE TECHNOLOGY APPRAISALS, GERMAN FEDERAL JOINT COMMITTEE AND SPANISH THERAPEUTIC POSITIONING REPORTRebollo, P. / Hashim, M. / Gottschalk, F. / Ortega, T. / Heeg, B. / Wilke, T. et al. | 2018
- S69
-
PCN326 - COMPARATIVE ANALYSIS OF ESMO MAGNITUDE OF CLINICAL BENEFIT SCALE VALUES ASSIGNED TO NSCLC CANCER DRUGS, VERSUS REAL WORLD DATA ON PRESCRIBING ACTIVITY AND LEVELS OF SATISFACTION IN THE EU5Caldeira, R. / Franceschetti, A. et al. | 2018
- S70
-
PCN333 - REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER CLASSIFIED AS RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPYByrne, K. / Moon, R. / Chang, J. / Hubanova, P. / Doherty, J.P. / Cappelleri, J.C. et al. | 2018
- S72
-
PCN345 - HEALTH STATE UTILITIES IN METASTATIC NSCLC: A STUDY OF MULTIPLE IMMUNO-ONCOLOGY TRIALSHuang, M. / Chandwani, S. / Insinga, R. / Burke, T. / Pellissier, J. / Pickard, A.S. et al. | 2018
- S73
-
PCN350 - EVALUATION OF DISEASE-SPECIFIC SKIN SYMPTOM ITEMS ON SKINDEX-29 IN CUTANEOUS T-CELL LYMPHOMA PATIENTS TREATED WITH MOGAMULIZUMAB OR VORINOSTATHudgens, S. / Floden, L. / Leoni, M. / Nikonova, E. / Quaglino, P. et al. | 2018
- S74
-
PCN356 - HOW SHOULD WE VALIDATE UTILITY MAPPING ALGORITHMS BEFORE USE? AN EXAMPLE IN NON-SMALL CELL LUNG CANCERGregory, J. / Dyer, M. / Hoyle, C. / Mann, H. / Hatswell, A.J. et al. | 2018
- S75
-
PCN362 - UNDERSTANDING PATIENT AND CLINICIAN PERCEPTIONS OF CELL AND GENE THERAPY IN ONCOLOGY USING QUALITATIVE ANALYSES OF SOCIAL MEDIA DATAMerinopoulou, E. / Cooper, O. / Hareendran, A. / Booth, A. / Faulkner, E.C. / Spinner, D.S. / Bruno, A. / Arjunji, R. et al. | 2018
- S76
-
PCN368 - CONCORDANCE BETWEEN PATIENTS AND CLINICIANS' REPORTING OF SYMPTOMATIC ADVERSE EVENTS IN CANCER CLINICAL TRIALS: A SYSTEMATIC REVIEWSparano, F. / Aaronson, N. / Cottone, F. / Piciocchi, A. / La Sala, E. / Anota, A. / Deliu, N. / Kieffer, J.M. / Efficace, F. et al. | 2018
- S79
-
PCN383 - ESTIMATING THE HEALTH IMPACT OF INCREASING BREAST AND CERVICAL CANCER SCREENING IN THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM AMONG LOW-INCOME WOMEN IN THE UNITED STATESEkwueme, D.U. / Pollack, L.M. / Hung, M. / Khushalani, J.S. / Miller, J.W. / Chang, S. et al. | 2018
- S82
-
PCP6 - HOW TO INTRODUCE MULTI-INDICATION BASED PRICING IN FINLAND?Karppinen, M.L. / Ihalmo, P. / Hjortsberg, C. et al. | 2018
- S83
-
PCP13 - IMPACT OF OUTCOME BASED ANNUITIES ON SMALL BIOTECH COMPANIESNevins, J.F. / Colasante, W. / Rahmati, D. et al. | 2018
- S84
-
PCP19 - AN UPDATED NICE POSITION ON THE EQ-5D-5L VALUATION SETCooper, S. / Bouvy, J. / Boysen, M. / Robertson, J. et al. | 2018
- S86
-
PCP34 - BIOSIMILARS: WHAT'S THE ISSUE?Mahi, L. / Barral, G. et al. | 2018
- S88
-
PCP48 - STABILITY OF RESULTS IN SIMULATION BASED HEALTH ECONOMIC MODELSGal, P. / Kovacs, V. et al. | 2018
- S90
-
PCP60 - EVOLVING STRATEGIES FOR GENERATING, SYNTHESIZING, AND VISUALIZING REAL WORLD EVIDENCE IN RARE DISEASESSzabo, S.M. / Johnston, K.M. et al. | 2018
- S91
-
PCP65 - KEY CONSIDERATIONS FOR THE COLLECTION OF PATIENT REPORTED OUTCOME (PRO) DATA IN REAL WORLD (RW) STUDIESRylands, A.J. / Boxell, E. / Bottomley, C.J. et al. | 2018
- S93
-
PCV7 - COMPARATIVE EFFECTIVENESS OF ORAL PROSTACYCLIN PATHWAY DRUGS ON HOSPITALIZATION AMONG PATIENTS WITH PULMONARY HYPERTENSION: A RETROSPECTIVE ADMINISTRATIVE CLAIMS STUDY IN A MANAGED CARE POPULATION IN THE USTsang, Y. / Drake, W. / Pruett, J. et al. | 2018
- S94
-
PCV12 - SHOULD KCENTRA BE ADDED FOR TREATMENT IN EMERGENCY WARFARIN REVERSAL?Oh, J. / Tsitarava, M. / Loh, F.E. et al. | 2018
- S96
-
PCV26 - LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALYFanelli, F. / Gazzi, L. / Heiman, F. / Peduto, I. / Pegoraro, V. et al. | 2018
- S97
-
PCV33 - THE RATE OF CARDIOVASCULAR EVENTS IN DIABETIC PATIENTS IN COLOMBIARomero, M. / Marino, C. / Cruz, A.M. / Rigueros, J. et al. | 2018
- S98
-
PCV38 - BUDGET IMPACT OF ALIROCUMAB IN THE MANAGEMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS IN ARGENTINAGiorgi, M.A. / Boissonnet, C.P. / Micone, P.V. / Gallo, M. / Stuart, P. / Giglio, N.D. et al. | 2018
- S99
-
PCV43 - BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ATORVASTATIN, PERINDOPRIL AND AMLODIPINE IN THE GREEK SETTINGStafylas, P. / Karaiskou, M. / Zouka, M. et al. | 2018
- S100
-
PCV49 - A REAL WORLD COST COMPARISON BETWEEN THOSE USING SALVIANOLATE INJECTION AND NOT AMONG CHINESE PATIENTS WITH CORONARY HEART DISEASE OR ANGINA PECTORIS: A RETROSPECTIVE DATABASE STUDYXu, Y. / Liu, H. / Gao, Y. / Xuan, J. et al. | 2018
- S102
-
PCV62 - THE 1-YEAR PRODUCTIVITY LOSS AND INDIRECT COSTS AFTER ACUTE CARDIOVASCULAR EVENTS IN POLANDDudek, D.Z. / Lamotte, M. / Sawicka, M. / Huczek, Z.J. / Depukat, R. / Rajtar-Salwa, R. / Krupiarz, M. / Duma, K. / Sidelnikov, E. et al. | 2018
- S103
-
PCV67 - STAR ANALYSIS AND FORECAST MODELLING TO ESTIMATE VALUE FOR MONEY OF ORAL ANTICOAGULANTSOrlowski, A. / Slater, R. / Ashton, R. / Glover, R. et al. | 2018
- S104
-
PCV74 - COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN SPANISH PATIENTS AT MODERATE, HIGH, AND VERY HIGH CARDIOVASCULAR RISKGarcía-Goñi, M. / Fácila, L. / Cinza, S. / Pinto, X. / Cortes, X. / Prades, M. / Aceituno, S. et al. | 2018
- S105
-
PCV80 - COST-EFFECTIVENESS OF NOACS IN PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN THE CZECH REPUBLICKolek, M. / Weber, J. / Karbusicka, M. / Vothova, P. / Mazan, P. / Duba, J. et al. | 2018
- S106
-
PCV85 - COST-EFFECTIVENESS OF BETRIXABAN COMPARED WITH ENOXAPARIN OR FONDAPARINUX FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HOSPITALISED ACUTE MEDICALLY ILL PATIENTS IN THE UNITED KINGDOMLaskier, V. / Guy, H. / Fisher, M. / Neuman, W.R. / Bucior, I. / Deitelzweig, S.B. / Cohen, A. et al. | 2018
- S107
-
PCV91 - VENOUS THROMBOEMBOLISM PROPHYLAXIS STRATEGIES FOR ELECTIVE TOTAL KNEE REPLACEMENT SURGERY: A COST-UTILITY ANALYSIS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATIONDawoud, D. / Wonderling, D. / Lewis, S. / Glen, J. / Griffin, X. / Reed, M. / Rossiter, N. / Stansby, G. / Hunt, B.J. / Chahal, J.K. et al. | 2018
- S108
-
PCV96 - HEALTHCARE RESOURCE UTLISATION IN PATIENTS ON LIPID-LOWERING THERAPIES OUTSIDE OF WESTERN EUROPE: FINDINGS OF THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY (ICLPS)Annemans, L. / Azuri, J. / Al-Rasadi, K. / Al-Zakwani, I. / Daclin, V. / Mercier, F. / Danchin, N. et al. | 2018
- S109
-
PCV103 - MANAGEMENT OF ATHEROGENIC DYSLIPIDEMIA IN REAL CLINICAL PRACTICE WITHIN THE SPANISH HEALTH SYSTEM ACCORDING TO CURRENT TREATMENT GUIDELINES: DESPEGA STUDYAceituno, S. / Millan, J. / Rodriguez, P. / Rodríguez de Miguel, M. / Melogno Klinkas, M. / Orera - Peña, M.L. et al. | 2018
- S110
-
PCV108 - PRESCRIBING CHOICE AND THE COST OF ANTICOAGULATION IN ATRIAL FIBRILLATION: A REAL WORLD STUDY COMPARING HEALTHCARE EXPENDITURE WITH WARFARIN AND APIXABANSchinle, P. / Keogh-Bootland, S. / du Feu, J. / Durno, K. / How, W.J. / Hill, N. / Gordon, J. / Sugrue, D. / Beresford, L. / Lister, S. et al. | 2018
- S111
-
PCV114 - PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH PRESCRIPTION OF NOVEL ORAL COAGULANTS IN A LARGE HEALTHCARE SERVICE PROVIDER IN ISRAELWeitzman, D. / Bourvine, L. / Tirosh, M. / Shalev, V. / Chodick, G. et al. | 2018
- S112
-
PCV120 - INDICATORS OF PRESCRIPTIVE APPROPRIATENESS AS A LEVER FOR PHARMACEUTICAL SUSTAINABILITY - THE CASE OF LOW MOLECULAR WEIGHT HEPARINSAndretta, M. / Degli Esposti, L. et al. | 2018
- S113
-
PCV127 - EFFECT OF LIPID TESTING INTERVAL ON CARDIOVASCULAR DISEASE AMONG NEWLY DIAGNOSED DYSLIPIDEMIA PATIENTSKo, A. / Choi, S. / Chang, J. / Park, S.M. et al. | 2018
- S114
-
PCV135 - NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS PRESCRIPTION MONITORING: HOW TO OPTIMIZE VIGILANCE IN STROKE PREVENTIONJacobs, M.S. / van Hulst, M. / Campmans, Z. / Tieleman, R.G. et al. | 2018
- S115
-
PCV145 - A SYSTEMATIC LITERATURE REVIEW (SLR) ON HEALTH STATE UTILITIES ASSOCIATED WITH ANGINA AND REVASCULARISATIONNatani, H. / Gogna, S. / Jindal, R. / Laires, P.A. / Cristino, J. et al. | 2018
- S116
-
PCV150 - HEALTH CARE RESOURCE USE AND QUALITY OF LIFE IN PATIENTS PRESCRIBED WITH SACUBITRIL/VALSARTAN IN PORTUGAL: A CROSS-SECTIONAL OBSERVATIONAL STUDY (PRIME STUDY)Afonso-Silva, M. / Laires, P.A. / Gonçalves, C. / Cary, M. / Guerreiro, J.P. / Romão, M. / Teixeira Rodrigues, A. et al. | 2018
- S117
-
PCV155 - EVALUATING THE IMPACT OF PHARMACIST INTERVENTION ON DISEASE KNOWLEDGE, ILLNESS PERCEPTIONS, AND BELIEF TOWARDS MEDICATIONS IN ACUTE CORONARY SYNDROME PATIENTS IN HONG KONGLee, V.W. / So, S.C. / Yeo, J. / Yan, B.P. et al. | 2018
- S119
-
PDB7 - THE EFFECT OF GLYCATED HEMOGLOBIN CONTROL ON DIABETIC FOOT COMPLICATIONSHammad, M.A. / Syed Sulaiman, S.A. / Sha'aban, A. / Mohamed Noor, D.A. et al. | 2018
- S120
-
PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONSBalijepalli, C. / Ayers, D. / Kandaswamy, P. / Ustyugova, A.V. / Pfarr, E. / Lund, S.S. / Druyts, E. et al. | 2018
- S122
-
PDB24 - BASELINE CHARACTERISTICS OF GERMAN DIABETES MELLITUS TYPE-2 PATIENTS WHO INITIATED INSULIN USAGE: A CLAIMS DATA ANALYSISGabler, M. / Picker, N. / Mueller, S. / Wilke, T. / Geier, S. / Försch, J. / Aberle, J. / Martin, S. / Riedl, M. et al. | 2018
- S123
-
PDB32 - SEX- AND SITE-SPECIFIC DIFFERENCES IN COLORECTAL CANCER RISK AMONG PEOPLE WITH TYPE 2 DIABETESOverbeek, J.A. / Kuiper, J.G. / van der Heijden, A.A. / Labots, M. / Haug, U. / Herings, R.M. / Nijpels, G. et al. | 2018
- S124
-
PDB40 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF TYPE 2 DIABETES &ENHANCEMENT PATIENT'S OUTCOMES AT COUNTRIES WITH HIGH INCIDENCE OF DIABETES EGYPT CASEAbotaleb, A. / Amin, M. et al. | 2018
- S125
-
PDB46 - CLINICAL AND ECONOMIC BURDEN OF TYPE 1 DIABETES IN REAL-LIFE SETTING IN SPAINSicras-Mainar, A. / Navarro-Artieda, R. et al. | 2018
- S126
-
PDB52 - ANNUAL COST OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TURKEYÖksüz, E. / Malhan, S. / Balbay, Y. / Bozkurt, E. / Ersoy, R. / Tetik, E. / Urganci, B. / Kamaci, E. / Cheynel, J. et al. | 2018
- S127
-
PDB58 - REIMBURSEMENT FOR TYPE 2 DIABETES MELLITUS PATIENTS HOSPITALIZED IN A MUNICIPAL HOSPITAL IN THE CZECH REPUBLICLoncak, V. / Bartak, M. / Rogalewicz, V. et al. | 2018
- S128
-
PDB64 - SHORT-TERM COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC IN JAPANESE PATIENTS WITH TYPE 2 DIABETESLanger, J. / Wolden, M.L. / Shimoda, S. / Sato, M. / Araki, E. et al. | 2018
- S129
-
PDB69 - COST-EFFECTIVENESS ANALYSIS OF ADDING PIOGLITAZONE TO INSULIN REGIMEN IN TYPE2 DIABETES IN IRANDavari, M. / Khorasani, E. / Savari Shojaei, R. / Akbari, Sari A / Saiyarsarai, P. et al. | 2018
- S130
-
PDB74 - IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN: A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLICRussel-Szymczyk, M. / Parekh, W. / Rychna, K. / Pöhlmann, J. / Hunt, B. et al. | 2018
- S131
-
PDB79 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIABogdanovic, M. / Fournier, M. / Vitezic, D. et al. | 2018
- S132
-
PDB84 - HETEROGENEITY OF TREATMENT EFFECT IN THE DIABETES PREVENTION PROGRAM: HIGH BASELINE RISK OF DEVELOPING DIABETES MAY PROVIDE A PLACE FOR METFORMIN IN DIABETES PREVENTION THAT USING OVERALL SAMPLE AVERAGE COSTS AND EFFECTS CONCEALSAlolayan, S. / Eguale, T. / Segal, A. / Doucette, J. / Rittenhouse, B. et al. | 2018
- S133
-
PDB89 - THE BURDEN OF PREGNANCY HYPERGLYCEMIA IN INDONESIAN WOMENFitria, N. / Utama, B. / Pradipta, I. / Schmidt, A. / van Asselt, A. / Postma, M.J. et al. | 2018
- S134
-
PDB95 - REAL WORLD EVIDENCE ON TYPE 2 DIABETES: IDENTIFICATION AND CHARACTERIZATION OF NON-INSULIN TREATED PATIENTS WHO FULFIL CONDITIONS FOR THAT TREATMENTAscenção, R. / Fiorentino, F. / Costa, J. / Gouveia, M. / Borges, M. et al. | 2018
- S135
-
PDB101 - THERAPY ADJUSTMENT IN ADULT T2DM PATIENTS WITH RENAL IMPAIRMENT TREATED WITH DPP-4 INHIBITORS IN THE UK: A RETROSPECTIVE COHORT STUDYSpanopoulos, D. / Poole, C. / Barrett, B. / Busse, M. / Roman, T. / Khunti, K. et al. | 2018
- S137
-
PDB114 - DRUG UTILIZATION STUDY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN AN ITALIAN REAL-WORLD SETTING: A RETROSPECTIVE STUDYDegli Esposti, L. / Perrone, V. / Saragoni, S. / Blini, V. / D'Avella, R. / Gasperini, G. / Lena, F. / Fanelli, F. / Gazzi, L. / Giorgino, F. et al. | 2018
- S138
-
PDB119 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH MEALTIME INSULIN CONCENTRATIONS AMONG PATIENTS WITH DIABETES IN ITALYMatza, L.S. / Osumili, B. / Stewart, K.D. / Perez, M. / Jordan, J. / Biricolti, G. / Romoli, E. / Losi, S. / Del Santo, S. / Spaepen, E. et al. | 2018
- S139
-
PDB125 - A DISCRETE CHOICE EXERCISE TO EVALUATE FACTORS DRIVING GROWTH HORMONE DEFICIENT (GHD) PATIENT PREFERENCES FOR INJECTION AND INJECTION DEVICE FEATURESMcNamara, M. / Westhead, H. / Gross, H. / Turner-Bowker, D.M. / Yaworsky, A. / Pleil, A. / Loftus, J.V. et al. | 2018
- S140
-
PDB132 - TYPE 2 DIABETES TREATMENT PATHS AND PATIENT OUTCOMES IN RESPONSE TO REIMBURSEMENT POLICY CHANGE IN FINLANDRuotsalainen, J. / Balcerzak, M. et al. | 2018
- S142
-
PGI8 - SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF LINACLOTIDE VERSUS OTHER ORAL CONSTIPATION TREATMENTS IN PATIENTS WITH CHRONIC CONSTIPATIONOkumura, H. / Tang, W. / Iwasaki, K. / Shoji, S. / Odaka, T. / Nakajima, A. et al. | 2018
- S143
-
PGI13 - REAL-LIFE BUDGET IMPACT OF DIRECT-ACTING ANTIVIRALS AGAINST HEPATITIS C VIRUS IN AN SPANISH PUBLIC HOSPITAL PHARMACYMargusino-Framiñán, L. / Cid-Silva, P. / Mena-de-Cea, A. / Vazquez-Rodriguez, P. / Rodriguez-Osorio, I. / Lopez-Calvo, S. / Pernas-Souto, B. / Martin-Herranz, I. / Castro-Iglesias, A. et al. | 2018
- S147
-
PGI39 - DARVADSTROCEL IN THE MANAGEMENT OF COMPLEX PERIANAL FISTULAS: THE ROLE OF PATIENT REGISTRY DATA COLLECTION TO SUPPORT PERFORMANCE-BASED RISK SHARING AGREEMENTSSchmetz, A. / Petrakis, I. / Khalid, J.M. / Minda, K. / Agboton, C. / Rawson, K. / Baumgart, D.C. et al. | 2018
- S148
-
PGI44 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) REPORT POSITIVE EXPERIENCE AFTER PARTICIPATING IN AN ONLINE QUANTITATIVE PREFERENCE SURVEYCook, N.S. / Balp, M. / Chatterjee, S. / Nagar, S. / Chirilov, A. / Weiss, O. / Schattenberg, J.M. / Schmid, A. / Hirschfield, G. / Kautz, A. et al. | 2018
- S149
-
PGI48 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) HAVE WORSE HEALTH RELATED QUALITY OF LIFE (HRQOL) THAN MATCHED CONTROLS: RESULTS FROM THE 2016 EU5 NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)Balp, M. / Krieger, N. / Przybysz, R. / Way, N. / Cai, J. / Zappe, D. / Mckenna, S.J. / Wall, G. / Janssens, N. / Tapper, E. et al. | 2018
- S151
-
PHP8 - THE ROLE OF GENERAL PRACTITIONERS IN TRAUMA CARE: VARIATION BY INJURY TYPE, REGION, PATIENT PROFILE, AND OVER TIMEHöglinger, M. / Knöfler, F. / Scholz, S. / Schaumann-von Stosch, R. / Eichler, K. et al. | 2018
- S152
-
PHP13 - USAGE OF DIETARY SUPPLEMENTS BY GYM VISITING ATHLETES – EFFECTS, AWARENESS AND CONSCIOUSNESSIpolyi, D. / Molnár, A. / Oláh, A. / Karácsony, I. / Pakai, A. / Brantmüller, É. / Boncz, I. / Breitenbach, Z. et al. | 2018
- S153
-
PHP19 - ANALYSIS OF ONE-DAY SURGERY INTERVENTIONS AMONG PATIENTS UNDER THE AGE OF 18 IN HUNGARYPónusz, R. / Boncz, I. / Németh, N. / Kovács, D. / Varga, V. / Molics, B. / Gresz, M. / Endrei, D. et al. | 2018
- S154
-
PHP25 - MENTAL HEALTH COMORBIDITIES AND ELEVATED RISK OF OPIOID USE IN ELDERLY BREAST CANCER SURVIVORS USING ADJUVANT ENDOCRINE TREATMENTSDesai, R.A. / Camacho, F. / Tan, X. / LeBaron, V. / Blackhall, L. / Balkrishnan, R. et al. | 2018
- S155
-
PHP31 - IMPACT OF EUROPEAN MEDICINES AGENCY (EMA) CLINICAL TRIAL TRANSPARENCY POLICIES ON HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS IN GERMANYJones, C. / Cocklin, S.L. et al. | 2018
- S156
-
PHP36 - EU5 AND PHARMACEUTICAL RESPONSES TO THE SPREAD OF CARBAPENEM-RESISTANT BACTERIA: A POLICY AND PIPELINE REVIEWCollings, H. / Palmer, T. / Tavella, F. et al. | 2018
- S157
-
PHP43 - EVIDENCE FOR HIGH RISK CLASS MEDICAL DEVICES VERSUS NEW DRUGS IN GERMANY: WHAT'S THE DIFFERENCE?Mueller, E. / Neeser, K. / Oelze, I. et al. | 2018
- S158
-
PHP48 - INTERNATIONAL REFERENCE PRICING OF PHARMACEUTICALS: APPLY LIBERALLY OR USE SPARINGLY?Lockwood, C. / Rodrigues, T. / Ando, G. et al. | 2018
- S159
-
PHP56 - EARLY ACCESS PROGRAMS: AN ANALYSIS SINCE THEIR ESTABLISHMENT IN ITALYD'Ausilio, A. / Seyed Khoei, N. / Lanati, E.P. et al. | 2018
- S160
-
PHP62 - HOME BREWED AUTOLOGOUS THERAPIES: CAN BIOPHARMA WIN THE WAR WITH DOMESTIC AUTOLOGOUS CELL & GENE THERAPY MANUFACTURERS?Khurana, S. / Kumar, A. / Sotou, D.S. et al. | 2018
- S161
-
PHP67 - CURRENT INITIATIVES & FUTURE OF E-HEALTH FUNDING PATHSKloc, K. / Lach, S. / Dusza, M. / Rémuzat, C. / Sediri, Y. / Palencia, R. / Abshagen, D. / Toumi, M. et al. | 2018
- S162
-
PHP72 - A NEW FRENCH FINANCIAL INCENTIVE TO BOOST INSULIN AND ETANERCEPT BIOSIMILARS PRESCRIBING: SIMULATION OF ECONOMIC IMPACTS FOR THE PUBLIC HOSPITALS OF PARISAdé, A. / Degrassat-Théas, A. / Bocquet, F. / Parent de Curzon, O. / Paubel, P. et al. | 2018
- S163
-
PHP78 - PRICING AND REIMBURSEMENT REFORMS IN SPAIN – A SYSTEMATIC ANALYSIS OF NATIONAL PRICING DECISIONS BY THE CIPMMacaulay, R. / Fernandez Dacosta, R. et al. | 2018
- S165
-
PHP93 - THE IMPACT OF SUPPLY CHAIN MARGINS AND VAT ON THE PRICES OF MEDICINES IN BULGARIA AND GREECECherneva, D. / Benisheva, T. et al. | 2018
- S166
-
PHP99 - OVER-THE-COUNTER MEDICINES USE AND ITS ASSOCIATION WITH RISK PERCEPTION AND SAFETY AMONG WOMEN VISITING COMMUNITY PHARMACIES IN MALAYSIAMittal, P. / Lai, K.Y. / Verma, R.K. / Hasan, S.S. et al. | 2018
- S167
-
PHP105 - A POPULATION-BASED DATA ANALYSIS OF DRUG PRESCRIPTION AND PATTERNS OF USE OF ANTIBIOTIC IN SOUTHERN ITALY POPULATIONMoreno Juste, A. / Guarino, I. / Russo, V. / Menditto, E. et al. | 2018
- S168
-
PHP110 - SUBSTANTIAL HEALTH GAINS FROM HEATH-SYSTEM-WIDE PATIENT BLOOD MANAGEMENT IMPLEMENTATION: ANALYTICS FOR EUROPEVandewalle, B. / Félix, J. / Ferreira, C. et al. | 2018
- S170
-
PHP121 - DISCRIMINATION IN ACCESS TO SCHEDULED SURGERY IN THE PORTUGUESE NHS: A SURVIVAL MODEL ANALYSISCima, J. / Almeida, A.S. et al. | 2018
- S171
-
PHP128 - 3F - FORMULA FOR FUNDING: RETHINKING THE PORTUGUESE HOSPITAL FUNDING SYSTEMLourenço, A. / Ventura, C. / Andrade, S. / Sousa, J. / Valadas, F. et al. | 2018
- S173
-
PHP139 - G-BA CONDITIONAL APPROVALS IN THE AMNOG PROCEDURE: IMPACT ON HTA OUTCOMES AND PRICEDehnen, J. / Petry, D. / Kruse, F. / Bercher, J. et al. | 2018
- S174
-
PHP144 - IMPACT OF A CREATIVE QUALITY IMPROVEMENT STRATEGY TO REDUCE PATIENT WAIT TIMES BETWEEN PRIMARY AND SPECIALITY CARE IN A TERTIARY, UNIVERSITY PUBLIC HOSPITAL IN PORTUGALCorreia, S. / Yantsides, C. / Amorim, A.P. / Monteiro, J.L. / Costa, L. / Gonçalves, A.M. / Azevedo, A. / Paiva, J.A. et al. | 2018
- S175
-
PHP151 - THE PERCEPTION OF THE PUBLIC ABOUT DISABILITY AND THE MEDICAL AND SOCIAL MODEL OF DISABILITY: A LITERATURE REVIEWFatoye, C. / Betts, A. / Odeyemi, A. / Fatoye, F. / Odeyemi, I. et al. | 2018
- S176
-
PHP156 - A SCENARIO ANALYSIS OF THE IMPACT OF TREATMENT SETTING ON HEALTH CARE COST AND TREATMENT OUTCOMESLewis, M. / Tavella, F. / Okhuoya, P. et al. | 2018
- S178
-
PHP167 - COUNTRY-LEVEL COST-EFFECTIVENESS THRESHOLD: INITIAL ESTIMATES IN REPUBLIC OF BELARUSKozhanova, I. / Sachek, M. et al. | 2018
- S180
-
PHP182 - EXTERNAL REFERENCE PRICING: CONSEQUENCES OF FRENCH PRICE DECREASES ON INTERNATIONAL TURNOVERLe Pen, C. / Sclison, S. / Ravonimbola, H. / Paolantonacci, J. / Baseilhac, E. / Savart, P. / Dorizon, D. / Vigneron, A. et al. | 2018
- S181
-
PHP188 - EVOLVING INDICATIONS – AN ANALYSIS OF INDICATION FIELDS OVER TIME BASED ON GERMAN PRESCRIBING INFORMATIONRavindra, S. / Boehler, Y. et al. | 2018
- S182
-
PHP193 - THE USE OF MEDTECH INNOVATION BRIEFINGS (MIBS) TO ENCOURAGE IMPLEMENTATION OF INNOVATIVE TECHNOLOGIES: A REVIEW OF PUBLISHED BRIEFINGS FROM 2014-2018Glen, F. / Pulfer, A. et al. | 2018
- S184
-
PHP206 - TUMOUR-AGNOSTIC AGENTS: ARE THEY FIT FOR REIMBURSEMENT?Khogeer, B. / Anjarwalla, N. / Doolub, N. / Grosvenor, A. et al. | 2018
- S185
-
PHP211 - ESTIMATION OF PHARMACEUTICAL CARE SERVICES IN UKRAINE: ISSUES AND WAYS FOR IMPROVEMENTDobrova, V. / Zupanets, I. / Shilkina, O. / Lishchyshyna, O. et al. | 2018
- S186
-
PHP217 - TIME TO MARKET AND PRICE COMPARISON FOR BIOSIMILAR DRUGS IN EU5López, N. / Prada, M. / Berard, I. / Schleich, W. / Melson, C. et al. | 2018
- S187
-
PHP222 - IDENTIFYING THE KEY DRIVERS AFFECTING THE REIMBURSEMENT OF THERAPEUTIC VACCINES IN EU5 COUNTRIES USING A WEB-BASED PORTAL TO ENGAGE PAYERSKumar Singh, K. / Clapton, G.S. / Narjal, M. / Yadav, V. / Shah, C.S. et al. | 2018
- S189
-
PHP233 - DIVERGENCE IN UK HTA RECOMMENDATIONS: NOT ALWAYS A NICE OUTCOMEGriffiths, E.A. et al. | 2018
- S190
-
PHP238 - CARER DISUTILITY: IS IT ACCURATELY CAPTURED IN NICE APPRAISALS?Ferizovic, N. / Marshall, J.D. et al. | 2018
- S191
-
PHP243 - DO DISEASE SEVERITY AND/OR QUALITY OF CLINICAL DATA INFLUENCE PRICING POLICY IN FRANCE? AN ANALYSIS ON ORPHAN DRUGS AND BLOOD CANCERS TREATMENTSVandewalle, C. / Charoy, M. / Heurtebis, J. / Desplanches, L. / Gauthier, M. / de Sauvebeuf, C. et al. | 2018
- S192
-
PHP252 - IS FACTOR ANALYSIS AS CREDIBLE AS OTHER TESTS OF DIFFERENCE AND ASSOCIATION FOR EVALUATING THE VALIDITY OF QUALITY OF LIFE MEASURES? ASSESSING THE CONVERGENT AND DISCRIMINANT VALIDITY OF THE WOMEN'S HEALTH QUESTIONNAIRE AGAINST THE EQ-5D-5L AND SF-6DKaambwa, B. / Ratcliffe, J. et al. | 2018
- S193
-
PHP258 - DEVELOPMENT OF A REAL WORLD EVIDENCE STUDY DESIGN TOOLXia, A. / Schaefer, C. / Szende, A. / Jahn, E. / Dunlop, W. et al. | 2018
- S194
-
PHP265 - LANDSCAPE ASSESSMENT OF A MENA HEALTHCARE DATABASE FOR USE IN HEALTH ECONOMICS MODELINGMaskineh, C. / Becker, R.V. / Kosremelli Asmar, M. / Bekhazi, H. / Sleilaty, G. et al. | 2018
- S195
-
PHP270 - POPULARITY OF NURSING PROFESSION AMONGST STUDENTS WHO ARE BEFORE THE CAREER CHOICEFerenczy, M. / Dudás, M. / Pakai, A. / Karácsony, I. / Boncz, I. / Rozmann, N. / Komlósi, K. / Oláh, A. et al. | 2018
- S197
-
PHP281 - THE METHODOLOGICAL DIFFERENCES OF EUROPEAN JOINT ASSESSMENT AND GERMAN HTA: AN EMPIRICAL APPROACHPanni, T. / Thiele, A. / Carls, A. / Wallstab, A. / Eberle, K. / Schleibner, S. et al. | 2018
- S198
-
PHP286 - RESPONSES OF ISPOR MEMBERS TO THE RECOMMENDATIONS OF THE SPECIAL TASK FORCE ON US VALUE ASSESSMENT FRAMEWORKSOyeye, O. / Johnson, K.I. et al. | 2018
- S199
-
PHP291 - SHAPING THE FUTURE OF EUROPEAN HEALTH TECHNOLOGY ASSESSMENTS: EXPERIENCES OF THREE PHARMACEUTICAL JOINT RAPID RELATIVE EFFECTIVENESS ASSESSMENTSWillemsen, A. / Estevão, S. / Dupree, R. et al. | 2018
- S200
-
PHP296 - MANAGED ACCESS AGREEMENTS (MAAS) AND CONTINUING DATA COLLECTION AFTER PROVISIONAL POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)Wordsworth, J. / Cork, D. / Curry, A. / Ralston, S. et al. | 2018
- S202
-
PHP307 - REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPEHanna, E. / Marre, C. / Toumi, M. et al. | 2018
- S203
-
PHP313 - ANALYSIS OF THE ANALYTICAL AND METHODOLOGICAL FRAMEWORK OF THE HEALTH ECONOMIC EVALUATION ASSESSMENTS DELIVERED IN FRANCECabout, E. / Launois, R. et al. | 2018
- S204
-
PHP319 - MANDATORY JOINT CLINICAL ASSESSMENT – WHAT IS THE ADDITIONAL INSIGHT FROM EU-NETHTA VS. EMA?Ecker, T. et al. | 2018
- S207
-
PHP337 - OFF-LABEL PRESCRIPTION OF DRUGS COMPARED TO PRESCRIPTION AFTER LABEL EXTENSION IN CHILDREN FOR GERMANYGohlke, A. / Kostev, K. / Kuschel, A. et al. | 2018
- S208
-
PHP342 - HOW TO MAXIMIZE THE EX-FACTORY PRICE IN PORTUGAL, WITH SIMULTANEOUS BENEFITS FOR PATIENTS AND PAYERS – AN INDUSTRY PERSPECTIVEHenriques, J. / Amorim, A. et al. | 2018
- S209
-
PHP348 - REGENERATIVE MEDICINE ADVANCED THERAPY: A BUDGET IMPACT ANALYSISHanna, E. / Marre, C. / Toumi, M. et al. | 2018
- S210
-
PHP353 - ROMANIAN EXPERIENCE WITH MANAGED ENTRY AGREEMENTS FOR DRUGSRadu, P. / Stoica, I. / Udroiu, P. et al. | 2018
- S211
-
PHP359 - IMPACT OF EXPEDITED MARKETING AUTHORISATION ON PRICING AND REIMBURSEMENT OUTCOMES FOR DRUGS IN THE US AND EU-5Izmirlieva, M.A. / Reinaud, F. / Ando, G. et al. | 2018
- S212
-
PHP365 - TRENDS AND CHARACTERISTICS OF MANAGED ACCESS AGREEMENTS APPROVED BY NICEMarsh, S.E. et al. | 2018
- S214
-
PIH7 - LONG-ACTING RECOMBINANT FSH (CORIFOLLITROPIN ALFA) VERSUS RECOMBINANT FSH AS ASSISTED REPRODUCTION TECHNIQUES IN THE MANAGEMENT OF INFERTILITY: A SYSTEMATIC REVIEW AND META-ANALYSISTaheri, S. / Varmaghani, M. / Heidari, E. / Yousefi, N. / Peiravian, F. et al. | 2018
- S216
-
PIH24 - MODELLED EFFECTS OF A PEDIATRIC TRIPLE-CHAMBER-BAG (3CB) SYSTEM ON PAYER COSTS AND CLINICAL OUTCOMES IN PRE-TERM NEONATES ACROSS FRANCE, GERMANY AND ITALYKriz, A. / Migliore, A. / Wright, A. / Piaggio, T. et al. | 2018
- S223
-
PIN18 - ESTIMATING THE BUDGET AND CLINICAL IMPACT OF INTRODUCING ISAVUCONAZOLE FOR THE TREATMENT OF PATIENTS WITH POSSIBLE INVASIVE ASPERGILLOSIS IN THE UNITED KINGDOMWeidlich, D. / Hicks, M.D. / Floros, L. / Patel, J. / Charbonneau, C. / Sung, A.H. et al. | 2018
- S224
-
PIN23 - CLINICAL AND ECONOMIC BURDEN OF INVASIVE MENINGOCOCCAL DISEASE IN FRANCEFievez, S. / Tin Tin Htar, M. / Goguillot, M. / Bénard, S. / Huang, L. et al. | 2018
- S225
-
PIN31 - ECONOMIC EVALUATION OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE ON CMV-SEROPOSITIVE RECEPTORS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT IN THE PORTUGUESE SETTINGFerreira, J. / Pereira, R. / Schelfhout, J. / Jiang, Y. et al. | 2018
-
PIH53 - COMPARISON OF THE EQ-5D-5L AND THE EQ-5D-3L USING INDIVIDUAL PATIENT DATA FROM REFORM TRIALCorbacho, B. / Keding, A. / Chuang, L. / Ramos-Goni, J.M. / Cockayne, S. / Torgerson, D. et al. | 2018
-
PHP369 - CHALLENGES IN ACHIEVING MARKET ACCESS SUCCESS FOR ADVANCED THERAPIES IN EUROPE: A CASE STUDYten Ham, R.M. / Hovels, A.M. / Hoekman, J. / Broekmans, A. / Leufkens, H.G. / Klungel, O. et al. | 2018
-
PIH44 - OLDER PEOPLE WITH LONG TERM CONDITIONS USING TECHNOLOGIES SUPPORTING HOME BASED CARE: PATTERNS OF RESOURCE USE, COSTS AND HEALTH RELATED QUALITY OF LIFEMateus, C. / Hernandez, A. / Palmer, T. / Varey, S. / Milligan, C. et al. | 2018
-
PIH19 - CAN THE PRINCIPLES AND GOOD PRACTICE OF BUDGET IMPACT ANALYSIS BE APPLIED IN SURGICAL CARE? - A MODEL FRAMEWORK FOR SURGICAL APPROACHESSong, C. / Liu, Y. / Liu, E. et al. | 2018
-
PHP358 - TIME-LIMITED G-BA RESOLUTIONS – A TOOL TO APPROPRIATELY MANAGE REIMBURSEMENT OF INNOVATIVE THERAPIES RECEIVING EXPEDITED REGULATORY APPROVALMacaulay, R. / Wang, G.D. / Majeed, B. et al. | 2018
-
PHP210 - DEVELOPMENT OF DRUG INNOVATIVNESS ASSESSMENT TOOL FOR DECISION-MAKING IN REIMBURSEMENT AND PRICINGLemeshko, V. / Fedyaeva, V. / Musina, N.Z. / Omelyanovskiy, V. / Khachatryan, G.R. et al. | 2018
-
PHP183 - PRICE DIFFERENCE OF MEDICINES DISPENSED IN COMMUNITY PHARMACIES AND IN THE HOSPITAL SECTOR : AN ANALYSIS ON THE MEDICINES FINANCED ON THE BASIS OF HOSPITAL SERVICE TARIFFSLaincer, A. / Degrassat-Théas, A. / Rouibah, F. / Parent de Curzon, O. / Poisson, N. / Paubel, P. et al. | 2018
-
PHP159 - PUBLIC HEALTH AND ECONOMIC VALUE OF A NATIONWIDE PATIENT BLOOD MANAGEMENT PROGRAMBrilhante, D. / Robalo Nunes, A. / Fonseca, C. / Mairos, J. / Félix, J. / Gonçalves, M. / Mota, M. / Ferreira, D. / Ferreira, C. / Andreozzi, V. et al. | 2018
-
PHP148 - SELF-PERCEIVED HEALTH INEQUALITIES BY INCOME DISTRIBUTION IN EUROPEAN UNIONSantos, J.V. / Freitas, A. et al. | 2018
-
PHP143 - ECONOMIC EVALUATIONS AND BUDGET IMPACT ANALYSES OF INNOVATIVE MEDICINES ACCORDING TO THE CATALAN HEALTH SERVICE STANDARDS: A QUALITATIVE ASSESSMENTAlonso, E. / Pastor, M. / Gasol, M. / Roig, M. / Guarga, L. / Delgadillo, J. et al. | 2018
-
PHP125 - COHORT TEMPORARY AUTHORISATION FOR USE IN FRANCE, FRENCH EXPERIENCE OF EARLY-ENTRY PROGRAM 2014-2018Weber, A. / Dussart, C. / Marre, C. / Toumi, M. et al. | 2018
-
PHP132 - CAN BLOCKCHAIN TECHNOLOGY IMPROVE THE QUALITY OF CLINICAL TRIAL EVIDENCE? – A SYSTEMATIC LITERATURE REVIEWKoufopoulou, M. / Arregui, M. / Lovelace, M. / Arisa, O. / Abogunrin, S. et al. | 2018
-
PHP126 - SCARS OF CHILD POVERTY IN ADULTS: A HEALTH PERSPECTIVECastañeda Diaz, B.D. et al. | 2018
-
PHP117 - TRENDS OF PRESCRIPTION FOR OFF-LABEL DRUGS IN KOREAN PEDIATRIC PATIENTS USING CLAIMS DATA: WITH A FOCUS ON CLINICAL AREAS AND PRIMARY DISEASESPark, E. / Kim, S. / Lee, J. / Kim, H. / Hahn, S. et al. | 2018
-
PHP102 - ARE SPECIFIC METHODOLOGICAL FRAMEWORKS REQUIRED FOR THE ECONOMIC EVALUATION OF GENE THERAPIES?Clay, E. / Kharitonova, E. / Ansaripour, A. / Aballea, S. / Toumi, M. et al. | 2018
-
PHP71 - HOW A NEW INNOVATION ASSESSMENT TOOL RELATES TO RECENT DRUG LAUNCHES FOR SPANISH NATIONAL ACCESSSolozabal, M. / Viayna, E. / Rubio, M. / Sumalla, M. / Otermin, A. / Gasche, D. / Planellas, L. / Callejo-Velasco, D. et al. | 2018
-
PHP60 - PAYER ARCHETYPING – EXPANDING HORIZONSCampbell, J. / Roibu, C. / Ivanova, H. / Macaulay, R. et al. | 2018
-
PHP69 - A REVIEW OF FUNDING PATHS FOR E-HEALTH SOLUTIONS IN THE EU5, US AND CANADAKloc, K. / Lach, S. / Dusza, M. / Rémuzat, C. / Sediri, Y. / Palencia, R. / Abshagen, D. / Toumi, M. et al. | 2018
-
PHP44 - EXPLORING THE KNOWLEDGE AND PERCEPTION OF GENERIC MEDICINE USE AMONG COMMUNITY PHARMACISTS IN SAUDI ARABIAAbanmi, M. / Alghamdi, A. et al. | 2018
-
PHP26 - EVOLUTION OF SICK PAY BENEFITS IN HUNGARY BETWEEN 2005 AND 2016Kovács, G. / Nogel, M. / Sebestyén, A. / Endrei, D. / Boncz, I. et al. | 2018
-
PHP14 - CO-CREATION OF PATIENT ENGAGEMENT QUALITY GUIDANCE AND QUALITY CRITERIA FOR MEDICINES DEVELOPMENT: AN INTERNATIONAL MULTI-STAKEHOLDER INITIATIVEDeane, K. / Skovlund, S.E. / Nafria, B. / Delbecque, L. / Gorbenko, O.V. / Pakarinen, C. / Brooke, N. / Hamoir, A.M. et al. | 2018
-
PGI51 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) REPORT HIGHER ECONOMIC BURDEN THAN CONTROLS: RESULTS FROM THE EU5 NATIONAL HEALTH AND WELLNESS SURVEYBalp, M. / Krieger, N. / Przybysz, R. / Way, N. / Cai, J. / Zappe, D. / Mckenna, S.J. / Wall, G. / Janssens, N. / Tapper, E. et al. | 2018
-
PGI50 - HAPPY TOMORROW BUT GLOOMING ELDERLY? SELF-ESTIMATION OF FUTURE HEALTH IN CROHN'S DISEASEPéntek, M. / Gulácsi, L. / Herszényi, L. / Palatka, K. / Lakatos, P.L. / Banai, J. / Brodszky, V. / Rencz, F. et al. | 2018
-
PGI49 - HUMANISTIC BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) – IN THE FIRST REAL-WORLD CROSS-SECTIONAL STUDY, SYMPTOMATIC NASH PATIENTS REPORT WORSE QUALITY OF LIFERatziu, V. / Geier, A. / Balp, M. / Mckenna, S.J. / Przybysz, R. / Cai, J. / Brass, C. / Howe, T. / Gavaghan, M. / Rosen, D. et al. | 2018
-
PGI11 - HIGH LEVELS OF REIMBURSED COST AND USE OF GASTROENTEROLOGICAL DRUGS IN FRANCERiviere, S. / Tuppin, P. / Sabate, J. / Gastaldi-Menager, C. et al. | 2018
-
PGI10 - COMPARATIVE EFFECTIVENESS OF PAN-GENOTYPIC THERAPIES FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS INFECTION IN BULGARIADjambazov, S. / Slavchev, G. / Encheva-Malinova, M. / Raduilov, B. / Vekov, T. et al. | 2018
-
PGI30 - POLISH THERAPEUTIC ALGORITHMS IN PATIENTS WITH COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASENowak, S. / Głażewska, J. / Reguła, J. et al. | 2018
-
PHP354 - THE IMPACT OF DATA PRIVACY REGULATIONS ON DRUG UTILIZATION DATA SHARING FOR INNOVATIVE PRICING ARRANGEMENTSMenner, J. / Lewandowska, P.K. et al. | 2018
-
PHP343 - CLINICAL DEVELOPMENT OF BIOLOGICS APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION, 2003-2016Alexander, G.C. / Ogasawara, K. / Wiegand, D. / Lin, D.H. / Breder, C.D. et al. | 2018
-
PHP315 - HOW FREQUENTLY IS PATIENT EXPERIENCE FORMALLY ASSESSED IN HEALTH TECHNOLOGY ASSESSMENTS? RESULTS FROM A SYSTEMATIC LITERATURE REVIEWSarri, G. / Kenny, J. / Freitag, A. / Mountian, I. / Szegvari, B. / Brixner, D. / Maniadakis, N. et al. | 2018
-
PHP277 - HOW DO BELLWETHER HTA AGENCIES EVALUATE BIOSIMILARS?Tiwana, S. / Adler, B. et al. | 2018
-
PHP279 - ASSESSMENT OF THE NICE FAST-TRACK APPRAISAL (FTA) PROCESSBrown, A. / Curry, A. / Ralston, S. / Cork, D. et al. | 2018
-
PHP283 - PHARMACEUTICAL CARE IN RESIDENTIAL SOCIO-HEALTH CENTERS: OPTIMISATION OF STORAGE AND DISPENSING CIRCUITMora-Santiago, M.R. / Aguilar DEL Valle, E. / Blanco Bermejo, C. / Ortiz, J. / Fernandez Huertas, L. et al. | 2018
-
PHP251 - PUBLIC-PRIVATE CONTRIBUTION TO BIOPHARMACEUTICAL DISCOVERIES: A BIBLIOMETRIC ANALYSIS OF BIOMEDICAL RESEARCH IN UKFabiano, G. / Marcellusi, A. / Favato, G. et al. | 2018
-
PHP227 - THE CURRENT REIMBURSEMENT LANDSCAPE FOR DIGITAL HEALTH IN THE UK: HOW FAR ARE WE FROM A CENTRALISED, NATIONAL SYSTEM?Braileanu, G. / Tavella, F. / Rousseau, B. et al. | 2018
-
PHP234 - EVALUATING THE IMPACT OF VALUE BASED PRICING (VBP) AND HTA ON PRICE LEVELS IN AN EU CONTEXTGranzow, H. / Ataide, J. / Van den Brandt, T. et al. | 2018
-
PDB65 - THE COST-EFFECTIVENESS OF METFORMIN IN PRE-DIABETICS: A SYSTEMATIC LITERATURE REVIEW OF HEALTH ECONOMIC EVALUATIONSGebregergish, S. / Henry, A. / Hashim, M. / Heeg, B. / Wilke, T. / Rauland, M. / Hostalek, U. et al. | 2018
-
PCV134 - REAL-WORLD DATA SOURCES FOR HEART FAILURE RESEARCH: A SYSTEMATIC REVIEWShaikh, S. / Agrawal, R. / Tripathi, P. / Bruce Wirta, S. / Maniadakis, N. / Suzart-Woischnik, K. / Denaxas, S. / Dobson, R. et al. | 2018
-
PCV151 - WHAT ARE THE MOST VALUED PATIENT OUTCOMES REGARDING MEDICAL CARE FOR FRENCH PATIENTS WITH HEART FAILURE? RESULTS FROM AN ONLINE PATIENT COMMUNITY (CARENITY.COM)De Monclin, C. / Debroucker, F. / Ullmann, E. et al. | 2018
-
PCV88 - PHARMACOECONOMICS OF ALIROCUMAB IN TREATMENT OF HYPERCHOLESTEROLEMIA: A SYSTEMATIC REVIEWScott, M. / Reyes, E. / Loh, F.E. et al. | 2018
-
PCV131 - IMPACT OF TIMELY INITIATION OF ANTIHYPERTENSIVE MEDICATIONS FOR PATIENTS WITH HYPERTENSION OR ELEVATED BLOOD PRESSUREHan, X. / McCombs, J.S. / Fox, D.S. et al. | 2018
-
PCV61 - PRODUCTIVITY LOSS AND LOCAL INDIRECT COSTS ASSOCIATED WITH ACUTE CORONARY SYNDROME AND STROKE IN SPAINEscobar Cervantes, C. / Gomez-Ulloa, D. / Elorriaga, A. / García, J.M. / Md, Freijo / Campos Tapias, I. / Gatell-Menchen, S. / Sidelnikov, E. / Alonso de Leciñana, M. et al. | 2018
-
PCV64 - THE DIRECT RESOURCE USE AND MEDICAL COSTS OF HEART FAILURE IN NOVA SCOTIA, CANADALevy, A. / Johnston, K. / Daoust, A. / Ignaszewski, A. / Rogula, B. / Lakzadeh, P. / Fortier, J. / Oh, P. et al. | 2018
-
PCN180 - PHARMACOECONOMIC ASSESSMENT OF FULVESTRANT VERSUS DD (DOXORUBICIN, DOCETAXEL) THERAPY IN POSTMENOPAUSAL WOMEN WITH METASTATIC ER (+) HER2 (-) BREAST CANCER IN UKRAINEMishchenko, O. / Adonkina, V. / Aristov, M. et al. | 2018
-
PCN177 - COST-EFFECTIVENESS OF TISAGENLECLEUCEL FOR ADULTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA : A CANADIAN SOCIETAL PERSPECTIVEYang, H. / Qi, C. / Zhang, J. / El Ouagari, K. et al. | 2018
-
PCN81 - BUDGET IMPACT ANALYSIS OF CDK4/6 INHIBITORS FOR THE FIRST LINE THERAPHY OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN THE RUSSIAN FEDERATIONAvxentyev, N.A. / Frolov, M.Y. / Pazukhina, E.M. et al. | 2018
-
PCN97 - ASSESSING THE IMPACT OF ACTIVE IDENTIFICATION OF PATIENTS APPROPRIATE FOR PALLIATIVE CARE ON RESOURCE UTILIZATION AND COSTS IN THE FINAL MONTH OF LIFELook Hong, N.J. / Liu, N. / Wright, F.C. / MacKinnon, M. / Seung, S.J. / Earle, C. / Gradin, S. / Sati, S. / Buchman, S. / Mittmann, N. et al. | 2018
-
PCN59 - ASSOCIATION BETWEEN HAZARD RATIOS OF SURROGATE TIME-TO-EVENT ENDPOINTS AND OVERALL SURVIVAL IN ADVANCED/METASTATIC CANCERSGebregergish, S. / Hashim, M. / Bartsch, R. / Ouwens, M.J. / Postma, M.J. / Heeg, B. et al. | 2018
-
PCN54 - IN-HOSPITAL RESOURCE USE FOR CANCER IN GERMANY FROM 2010 TO 2015Wahler, S. / Wahler, E. / Müller, A. et al. | 2018
-
PCN69 - BUDGET IMPACT OF SUBSTITUTING BIOSIMILAR TRASTUZUMAB (CT-P6) IN TREATING GASTRIC CANCER AND BREAST CANCER IN 28 EUROPEAN COUNTRIESSuh, D. / Lee, S. et al. | 2018
-
PCN60 - REAL-WORLD OVERALL SURVIVAL OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANYGottschalk, F. / Cizova, D. / Mueller, S. / Myers, D. / Wilke, T. / Maywald, U. et al. | 2018
-
PCN39 - ESTIMATING THE MEAN PROGRESSION-FREE SURVIVAL OF NIRAPARIB, OLAPARIB AND RUCAPARIB COMPARED TO ROUTINE SURVEILLANCE FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT OVARIAN CANCER WITHOUT A BRCA MUTATIONFisher, M. / Guy, H. / Walder, L. et al. | 2018
-
DS3 - REGORAFENIB IN METASTATIC COLORECTAL CANCER: COST-EFFECTIVENESS ANALYSIS BASED ON PROPENSITY SCORE WEIGHTED COHORT OF CZECH REGISTRYMlcoch, T. / Tereza, H. / Zadak, J. / Vesela, S. / Marian, M. / Dolezal, T. et al. | 2018
-
PCV8 - IMPACT OF EXERCISE-BASED REHABILITATION IN PATIENTS WITH HEART FAILURE (EXTRAMATCH II) ON EXERCISE CAPACITY AND HEALTH-RELATED QUALITY OF LIFE: A META-ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM RANDOMISED TRIALSCiani, O. / Walker, S. / Taylor, R.S. et al. | 2018
-
PCV5 - REAL-WORLD LDL-C CHANGES EXPERIENCED WITH LOMITAPIDE MODELLED TO POTENTIALLY INCREASE LIFE-EXPECTANCY IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)Ager, M. / Phillips, H. et al. | 2018
-
PCV15 - DRUGS FOR TREATING SEVERE HYPERTENSION IN PREGNANCY: A NETWORK META-ANALYSIS AND TRIAL SEQUENTIAL ANALYSIS OF RANDOMIZED CLINICAL TRIALSSridharan, K. / Sequeira, R.P. et al. | 2018
-
PCP39 - INNOVATION IN IDENTIFYING BARRIERS TO ACCESS AND IMPROVING THE QUALITY OF CANCER CARE AND TREATMENT FOR VULNERABLE AREAS PEOPLE, ARGENTINA 2017Carlino, O.L. / Balbuena, K.G. et al. | 2018
-
PCV35 - SECONDARY PREVENTION FOR CARDIOVASCULAR DISEASE: DEFINITION OF POPULATION AND EVALUATION OF OUTCOMES USING REAL WORLD DATASciattella, P. / Mennini, F.S. et al. | 2018
-
PCP9 - GENE THERAPY CRISIS: HOW WILL THE CURRENT PRODUCT PIPELINE AFFECT THE PHARMACEUTICAL INDUSTRY AND HEALTHCARE SYSTEMS?Fabiani, M. / Sogokon, P. / Morrison, S. et al. | 2018
-
PCP59 - IDENTIFICATION, SELECTION AND MEASUREMENT OF OUTCOMES TO FACILITATE THE USE OF BIG DATA: A TOOLKITHarrison, K. / Stegenga, H. / Jonsson, P. et al. | 2018
-
PCN378 - MINIMALLY IMPORTANT DIFFERENCES FOR INTERPRETING EORTC QLQ-C30 SCORES IN MELANOMA, BREAST CANCER AND HEAD AND NECK CANCER PATIENTS ON BEHALF OF THE EORTC BREAST, HEAD AND NECK, MELANOMA AND QUALITY OF LIFE GROUPSMusoro, Z.J. / Coens, C. / Fiteni, F. / Pogoda, K. / Cardoso, F. / Tribius, S. / Singer, S. / Oosting, S. / Russell, N. / Simon, C. et al. | 2018
-
PCN363 - A BEST–WORST SCALING SURVEY OF PREFERENCES OF CURRENT, PAST AND NEVER SMOKERS FOR ADVERSE EFFECTS OF SMOKING IN JAPANMori, T. et al. | 2018
-
PCP1 - COMPARISON OF THE GERMAN MIXED PRICE MODEL AND INDICATION-SPECIFIC PRICING FOR MULTI-INDICATION PRODUCTS IN ONCOLOGYMossmann, W. / Scherrer, F. et al. | 2018
-
PCN325 - COMPARING THE ROLE OF DIFFERENT SPECIALITIES IN THE MANAGEMENT OF PROSTATE CANCER IN FRANCE AND ITALY: INSIGHTS FROM A REAL-WORLD STUDYMpima, S. / Casey, C. / Nasuti, P. et al. | 2018
-
PCN336 - TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL IN PORTUGALSilva Miguel, L. / Paquete, A.T. / Guerreiro, R. / Fiorentino, F. / Costa, J. / Borges, M. et al. | 2018
-
PCN285 - PRICE DIFFERENCES FOR ONCOLOGY DRUGS ACROSS THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT.Cuesta, M. / Prada, M. / Berard, I. / Vollmer, L.M. / Guterres, S. et al. | 2018
-
PCN115 - ASSESSING THE ECONOMIC BURDEN AND 30-DAY READMISSION RATES AMONG PATIENTS WITH BLADDER CANCER IN THE US VETERANS HEALTH ADMINISTRATION POPULATIONBorra, S. / Lin, C. / Wang, L. / Yuce, H. / Baser, O. et al. | 2018
-
PHP178 - ROLE OF SUPPLEMENTARY AND COMPLEMENTARY PRIVATE HEALTH INSURANCE IN SELECTED COUNTRIESAlmasi, T. / Fasseeh, A.N. / Elezbawy, B. / George, M. / Abouelmaged, E. / Arnaiz, F. / Abaza, S.A. / Nagy, B. / Kaló, Z. et al. | 2018
-
PHP123 - REGIONAL DISPARITIES IN THE DISTRIBUTION OF HEALTH CARE FACILITIES: VISUALIZATION OF REGIONAL MEDICAL CARE SUPPORT HOSPITALSShimizu, S. / Shinjo, D. / Sakata, N. / Ishikawa, K.B. / Fushimi, K. et al. | 2018
-
PHP108 - DETERMINANTS OF THE UPTAKE OF ROTAVIRUS AND PNEUMOCOCCAL CONJUGATE VACCINES IN ETHIOPIAWondimu, A. / Postma, M.J. et al. | 2018
-
PHP109 - COST OF UNLICENCED AND ORPHAN MEDICINES IN TURKEY, KAZAKHSTAN AND POLANDAtikeler, K. / Goettsch, W. / Baran, A. / Gaitova, K. / Bayar, B. / Czech, M. / Leufkens, H.G. et al. | 2018
-
PHP77 - EFFECT OF NEW INDICATIONS ON THE PRICE DEVELOPMENT OF NEW MEDICINAL PRODUCTS IN GERMANYBot, D. / Linstaedt, J. / Ecker, T. et al. | 2018
-
PHP73 - FACTORS INFLUENCING THE DURATION OF MEDICINE PRICE NEGOCIATION IN FRANCEPetri, C. / Holscher, E. / Borget, I. / Bertin, L. et al. | 2018
-
PHP35 - AMNOG EARLY BENEFIT ASSESSMENT (EBA) AND MARKET PENETRATION OF NEW DRUGS FOR MELANOMA, MULTIPLE SCLEROSIS AND DIABETES MELLITUS IN GERMANYMathes, J. / Höer, A. et al. | 2018
-
PHP18 - COULD THE ONE-DAY SURGERY PLAY A SIGNIFICANT ROLE IN CATARACT WAITING LIST REDUCTION PROCESS IN HUNGARY?Pónusz, R. / Boncz, I. / Németh, N. / Kovács, D. / Varga, V. / Molics, B. / Gresz, M. / Endrei, D. et al. | 2018
-
PHP3 - SURVEY OF THE PATIENT ORGANISATION SUBMISSION PROCESS (POSP) TO THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE) IN IRELANDGorry, C. / Hanevy, A. / O'Leary, A. / Tilson, L. / Barry, M. et al. | 2018
-
PGI1 - ADVERSE EVENTS ASSOCIATED WITH THE TREATMENT OF INFLAMMATORY BOWEL DISEASE IN GERMANYWilke, T. / Groth, A. / Long, G.H. / Tatro, A.R. / Sun, D. et al. | 2018
-
PGI34 - A COST SAVING MEASURE FROM THE UTILISATION OF BIOSIMILAR INFLIXIMAB IN THE IRISH SECONDARY CARE SETTINGO'Brien, G.L. / Carroll, D.G. / Walshe, V. / Mulcahy, M. / Courtney, G. / O'Mahony, C. / Byrne, S. et al. | 2018
-
PGI43 - WHAT DO PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) VALUE AND NEED? RESULTS FROM A QUANTITATIVE PATIENT PREFERENCE STUDYCook, N.S. / Balp, M. / Chatterjee, S. / Nagar, S. / Chirilov, A. / Weiss, O. / Schattenberg, J.M. / Schmid, A. / Hirschfield, G. / Kautz, A. et al. | 2018
-
PGI29 - GENDER DIFFERENCES IN CLINICAL PROFILE AND HEALTHCARE UTILIZATION OF NON ALCOHOLIC FATTY LIVER PATIENTSGoldshtein, I. / Chodick, G. / Shibolet, O. et al. | 2018
-
PDB112 - TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIESNorrbacka, K. / Divino, V. / Boye, K. / Lebrec, J. / Dekoven, M. et al. | 2018
-
PDB113 - PSYCHOMETRIC EVALUATION OF A SELF-REPORTED MEDICATION ADHERENCE MEASURE ADAPTED TO COMMUNITY PHARMACY PRACTICE : THE QUESTIONNAIRE " TOP SCORE "Michiels, Y. / Bugnon, O. / Vergez, G. / Allaert, F. et al. | 2018
-
PDB104 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF DIABETES IN EGYPTAmin, M. / Abotaleb, A. et al. | 2018
-
PHP338 - PATIENT INVOLVEMENT IN CLINICAL PRACTICE GUIDELINE DEVELOPMENT PROCESSES: DOES REALITY ALIGN WITH INTENT?Desai, B. / Oehrlein, E. / Ganser, T.R. / Ngo, M. / Perfetto, E.M. et al. | 2018
-
PHP322 - REAL-WORLD DATA : WHAT ARE THE USE AND REQUIREMENTS IN HEALTH-ECONOMIC APPRAISALS IN REINSCRIPTION BY THE FRENCH HAUTE AUTORITE DE SANTE (HAS)?Petitjean, A. / Roze, S. et al. | 2018
-
PHP327 - CATEGORISATION OF OBSERVATIONAL STUDIES REQUESTED BY THE EMA AND SUBMITTED TO THE EUROPEAN UNION (EU) ELECTRONIC REGISTER OF POST-AUTHORIZATION STUDIES (PAS)Palacios, L. / De Cock, E. et al. | 2018
-
PHP332 - INTRODUCTION OF MOBILE HEALTH TECHNOLOGY AT THE PRIMARY HEALTHCARE LEVEL IN MONGOLIAChimeddamba, O. et al. | 2018
-
PHP308 - CONSIDERATION OF LEGAL ASPECTS IN HTA – CAN A SYSTEMATIC AND PRAGMATIC METHODOLOGICAL APPROACH BE IDENTIFIED IN GERMAN HTA?Siering, U. / Özdemir, D. / Thys, S. / Altenhofen, L. / Mischke, C. et al. | 2018
-
PHP276 - A REVIEW OF THE IMPACT OF INTEGRATED SCIENTIFIC ADVICE FOR THE OPTIMISATION OF EVIDENCE GENERATION FOR HTA APPRAISALSNg, T. / Ziomek, J. / Delaitre-Bonnin, C. / Bending, M.W. et al. | 2018
-
PHP257 - AN ANALYSIS AND FEASIBILITY ASSESSMENT OF INDICATION-SPECIFIC PRICING AS A MEANS TO IMPROVE PATIENT ACCESS TO MEDICINES AND REINFORCE INCENTIVES FOR INNOVATIONBaker, T. / Marinoni, G. / Houslay, D. / Tao, T. / Garbaz, O. / Malhotra, S. et al. | 2018
-
PHP261 - IMPACT OF DYNAMIC CHANGES OF THE DEFINITION OF THE APPROPRIATE COMPARATIVE THERAPY (ACT) ON MARKET ACCESS PERFORMANCE OF NEW ACTIVE SUBSTANCES IN GERMANYSchikowski, M. / Gibson, L. / Mrosowsky, T. / Schönermark, M. et al. | 2018
-
PHP219 - MEDICINRÅDET AND THE NEW HOSPITAL DRUG APPRAISAL PROCESS IN DENMARK – THE STORY SO FARRothwell, S. / Macaulay, R. et al. | 2018
-
PHP232 - A COMPARISON OF COST-EFFECTIVENESS ASSESSMENTS BETWEEN NICE AND SMC TECHNOLOGY APPRAISALSGriffiths, E.A. / Hendrich, J. et al. | 2018
-
PDB71 - ASSESSING THE RELATIVE COST-EFFECTIVENESS OF EMPAGLIFLOZIN AND CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES PATIENTS WITH EXISTING CARDIOVASCULAR DISEASE IN THE UKWebster, S. / Hau, N. / Ustyugova, A.V. / Kansal, A.R. / Reifsnider, O. et al. | 2018
-
PDB55 - ECONOMIC ANALYSIS OF TYPE-2 DIABETES MELLITUS IN VIETNAM: A RETROSPECTIVE STUDY AT A DISTRICT HOSPITAL, BA RIA - VUNG TAU PROVINCENguyen, T.T. et al. | 2018
-
PDB20 - PERSISTENCE TO LIRAGLUTIDE THERAPY IS ASSOCIATED WITH BETTER GLYCEMIC AND WEIGHT CONTROL IN PATIENTS WITH TYPE 2 DIABETESMelzer Cohen, C. / Chodick, G. / Nystrup Husemoen, L.L. / Rhee, N.A. / Shalev, V. / Karasik, A. et al. | 2018
-
PDB16 - COMPARE RENAL FUNCTIONAL PRSERVATION OUTCOME OF SGLT2 INHIBITOR VS DPP4 INHIBITOR IN PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY OF JAPANESE COMMERCIAL DATABASE WITH ADVANCED ANALYTICS APPROACHZhou, F.L. / Watada, H. / Tajima, Y. / Berthelot, M. / Kang, D. / Esnault, C. / Shuto, Y. / Maegawa, H. / Koya, D. et al. | 2018
-
PCV156 - CORRELATION OF THE DISEASE-SPECIFIC CSS/NYHA CLASSIFICATION WITH GENERIC HEALTH-RELATED QUALITY OF LIFE IN CORONARY ARTERY DISEASE PATIENTSLavikainen, P.T. / Hartikainen, J. / Miettinen, H. / Viljakainen, M. / Martikainen, J.A. / Tolppanen, A. / Roine, R.P. et al. | 2018
-
PDB8 - FACTORS ASSOCIATED WITH UNCONTROLLED GLYCEMIA AMONG OUTPATIENTS WITH TYPE 2 DIABETESHammad, M.A. / Syed Sulaiman, S.A. / Mohamed Noor, D.A. et al. | 2018
-
PCV75 - AN UPDATED COST-EFFECTIVENESS PAIRWISE ANALYSIS OF APIXABAN AND WARFARIN FOR STROKE PREVENTION IN PATIENTS WITH NON- VALVULAR ATRIAL FIBRILLATION IN FRANCELanitis, T. / Bregman, B. / Maunoury, F. / Prawitz, T. / Gaudin, A. / Cotté, F. et al. | 2018
-
PCV69 - COST-EFFECTIVENESS OF IVABRADINE AS A PHARMACOTHERAPY OPTION FOR PATIENTS WITH CONGESTIVE HEART FAILURE: A SYSTEMATIC REVIEWKumar, S. / Loh, F.E. et al. | 2018
-
PCN223 - WHAT UNDERLIES THE OBSERVED HOSPITAL VOLUME-OUTCOME RELATIONSHIP?Huguet, M. / Joutard, X. / Ray-Coquard, I. / Perrier, L. et al. | 2018
-
PCV63 - ECONOMIC BURDEN ASSOCIATED WITH SECONDARY CARDIOVASCULAR (CV) EVENTS – A SYSTEMATIC LITERATURE REVIEWCholasamudram, S. / Yenamandra, J. / Jindal, R. / Cristino, J. et al. | 2018
-
PCN239 - NICE AND THE CANCER DRUGS FUND: APPRAISING TREATMENTS FOR RARER CANCERS IN ENGLANDEdwards, H.K. / Kent, E. / Landells, L.J. et al. | 2018
-
PCN228 - REAL-WORLD USE OF PEMBROLIZUMAB AND NIVOLUMAB FROM CLINICAL TRIALS TO MARKET LAUNCH: WHAT CAN BE LEARNED?Bouee Benhamiche, E. / Le Bihan Benjamin, C. / Rocchi, M. / Negellen, S. / Bousquet, P.J. et al. | 2018
-
PDB11 - CHART REVIEW ANALYSIS OF INSULIN GLARGINE 300 AND INSULIN GLARGINE 100 USE IN FRANCE, SPAIN, AND GERMANYEscalada, J. / Bonnet, F. / Wu, J. / Bonnemaire, M. / Gupta, S. / Cambron-Mellot, M.J. / Nicholls, C. / Müller-Wieland, D. et al. | 2018
-
PCN217 - KEEPING UP WITH THE COMPARATORS: TRENDS IN TARGETED CANCER THERAPIES BECOMING RIGHT COMPARATORS FOR PAYERSWijnands, T. / Strydom, M. / Spinas, N. / van Engen, A. et al. | 2018
-
PCN172 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB IN UNTREATED ALK-REARRANGED NSCLC ITALIAN PATIENTSBellone, M. / Pradelli, L. / Masetti, L. / Recchia, A. / Orfanos, P. et al. | 2018
-
PCN182 - COST-EFFECTIVENESS RANDOMIZED STUDY OF LAPAROSCOPIC VERSUS OPEN BILATERAL INGUINAL HERNIA REPAIRNuñez Alfonsel, J. / Hidalgo, A. / Ielpo, B. / Quijano, Y. / Vicente, E. et al. | 2018
-
PCN135 - DOES PATIENT SELECTION CRITERIA TRANSLATE INTO COST SAVINGS IN PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER CHEMOTHERAPY FAILURE IN SPAIN?Ramon, A. / Paladio, N. / Male, N. et al. | 2018
-
PCN107 - BURDEN AND COSTS OF ACUTE MYELOID LEUKAEMIA IN PORTUGALGuerreiro, R. / Miguel L, Silva / Costa, J. / Paquete, A.T. / Alarcão, J. / Fiorentino, F. / Borges, M. et al. | 2018
-
PCN88 - NET IMPACT ANALYSIS OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA FOR QUEBECPettigrew, M. / Garces, K. et al. | 2018
-
PCN113 - EVALUATING THE ECONOMIC IMPACT OF NOVEL AGENTS FOR TREATING MULTIPLE MYELOMASiskou, O. / Terpos, E. / Galanis, P. / Vasilakopoulos, T. / Tsirigotis, P. / Batsis, I. / Megalakaki, A. / Pouli, A. / Konstantakopoulou, O. / Karagkouni, I. et al. | 2018
-
PCN104 - ECONOMIC ANALYSIS OF COSTS AND RESOURCE CONSUMPTION OF IXAZOMIB IN PATIENTS WITH RELAPSED / REFRACTORY MULTIPLE MYELOMA IN AUSTRIAWalter, E. / Lazic-Peric, A. / Schalle, K. / Voit, M. et al. | 2018
-
PCN76 - BUDGET IMPACT ANALYSIS OF AFATINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC NON–SMALL-CELL LUNG CANCER IN CHINAZhang, Y. / Samuelsen, C.H. / Griebsch, I. / Yao, Z. et al. | 2018
-
PCN61 - REAL-WORLD PROGRESSION-FREE SURVIVAL OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANYCizova, D. / Gottschalk, F. / Mueller, S. / Myers, D. / Wilke, T. et al. | 2018
-
PCN64 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING METHODOLOGIES ADJUSTING FOR OVERALL SURVIVAL IN THE PRESENCE OF TREATMENT SWITCHINGGurskyte, L. / Muresan, B. / Kulakova, M. / Postma, M.J. / Ouwens, M.J. / Heeg, B. et al. | 2018
-
PCN33 - SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES FOR FIRST-LINE TREATMENTS IN ADVANCED OR METASTATIC RENAL CELL CARCINOMABregman, C. / Supiot, R. / Pacou, M. / Doan, J. / Dale, P. / Malcolm, B. et al. | 2018
-
QL2 - HEALTH UTILITY OF PATIENTS WITH TYPE 2 DIABETES AND VARIOUS SINGLE AND MULTIPLE COMPLICATIONS IN CHINA: A NATIONWIDE SURVEYWang, P. / Li, C. et al. | 2018
-
PCN14 - COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN THE UNITED STATESDaSilva, C. / Noone, J.M. / Wriede, V. et al. | 2018
-
QL1 - VALIDATION OF PROMIS PREFERENCE SCORE (PROPR) IN GERMAN PATIENTS WITH RHEUMATOLOGICAL CONDITIONSKlapproth, C.P. / Obbarius, A. / Merbach, M. / Rose, M. / Fischer, F. et al. | 2018
-
PCV42 - A PHARMACOECONOMIC ANALYSIS OF THE USE OF APIXABAN FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN RUSSIAN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATIONRyazhenov, V.V. / Gorokhova, S.G. / Gorokhov, V. et al. | 2018
-
PCV24 - SAFETY AND EFFECTIVENESS OF CONTEMPORARY P2Y12 INHIBITORS IN EAST ASIAN PATIENTS WITH ACUTE CORONARY SYNDROMES: A NATIONWIDE POPULATION-BASED COHORT STUDYYun, J.E. et al. | 2018
-
PCV27 - HEART FAILURE SIGNS AND SYMPTOMS AND REFERRALS TO HOSPITAL ARE REDUCED FOLLOWING SACUBITRIL/VALSARTAN TREATMENT IN THE PRIMARY CARE AND CARDIOLOGIST SETTING IN GERMANYWachter, R. / Klebs, S. / Balas, B. / Kap, E.J. / Engelhard, J. / Schlienger, R. / Fonseca, A.F. / Proenca, C.C. / Bruce Wirta, S. et al. | 2018
-
PCP68 - MEDICAL ACCESS STRATEGY TO IMPROVE ACCESS TO INNOVATIVE AND EXPENSIVE THERAPY IN FRANCECohen, S. / Paubel, P. / Monchecourt, F. et al. | 2018
-
PCP69 - APPLICATION DECREE OF JARDE LAW: EXPERIENCE FROM A NON-INTERVENTIONAL STUDY IN FRANCEGuillemot, J. / Syed, I.A. / Jamet, N. et al. | 2018
-
PCP37 - THE CONFIDENTIALITY REGARDING DRUGS PRICING AND REIMBURSEMENT IN ROMANIAPaveliu, M.S. / Radu, P. et al. | 2018
-
PCN375 - ASSESSING NUTRITIONAL STATUS AMONG PATIENTS WITH LUNG CANCERPakai, A. / Istlstekker, I. / Vajda, R. / Csákvári, T. / Váradyné Horváth, Á. / Póhr, K. / Fusz, K. / Boncz, I. / Oláh, A. et al. | 2018
-
PCN359 - COMPARISON OF INSTITUTIONAL AND HOME HOSPICE CAREDeleróza, A. / Fusz, K. / Pusztai, D. / Csákvári, T. / Váradyné Horváth, Á. / Á, Müller / Boncz, I. / Oláh, A. et al. | 2018
-
PCN317 - THE CANCER DRUGS FUND: KEY UNCERTAINTIES, DATA COLLECTION PLANS, ANALYTICAL METHODS AND USE OF THE SYSTEMATIC ANTI-CANCER THERAPY (SACT) REAL WORLD DATA SETLatimer, N.R. et al. | 2018
-
PCN305 - NICE AND THE CANCER DRUGS FUND – CAN OBSERVATIONAL EVIDENCE INFORM FUNDING DECISIONS IN ONCOLOGY?Walsh, S. / Liu, L.W. / Macaulay, R. et al. | 2018
-
PCN289 - HOW ACCELARATED IS PATIENTS' ACCESS TO NEW ONCOLOGY PRODUCTS IN THE NEW ERA OF CANCER DRUG'S FUND IN ENGLAND?Bates, B.E. / Tsoumani, E. et al. | 2018
-
PCN332 - REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE (VTD) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIESAnjo, J. / Rider, A. / Bailey, A. / Gaudig, M. et al. | 2018
-
PCN287 - ANALYSIS OF IMPACTS OF THE SUPPLEMENTARY SCHEMES ON THE DRUG REIMBURSEMENT DECESION-MAKING UNDER THE POSITIVE LIST SYSTEM IN KOREAK.I.M., T. et al. | 2018
-
AC2 - USE OF MEDICINE PRICING AND REIMBURSEMENT POLICIES FOR UNIVERSAL HEALTH COVERAGE IN INDONESIAWasir, R. / Irawati, S. / Makady, A. / Postma, M.J. / Goettsch, W. / Feenstra, T. / Buskens, E. et al. | 2018
-
PCN339 - SPEAR-BLADDER (STUDY INFORMING TREATMENT PATHWAY DECISION IN BLADDER CANCER): TIMING OF TREATMENT FOLLOWING FIRST-LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC UROTHELIAL CANCER IN THE COMMUNITY ONCOLOGY SETTING IN THE UNITED STATESDoshi, G. / Bhanegaonkar, A. / Bharmal, M. / Phatak, H. / Boyd, M. / Aguilar, K.M. / Kearney, M. et al. | 2018
-
CV1 - A COST-EFFECTIVENESS ANALYSIS OF MULITI-GENE PHARMACOGENETIC TESTING IN ACUTE CORONARY SYNDROME PATIENTS FOLLOWING PERCUTANEOUS CORONARY INTERVENTIONDong, O. / Lee, C.R. / Wheeler, S.B. / Voora, D. / Dusetzina, S.B. / Wiltshire, T. et al. | 2018
-
AC1 - OUTCOME OF NEW DRUG NEGOTIATION PROCESS IN ITALY: APPROVAL CONDITIONS (2015-2018)Lidonnici, D. / Lanati, E.P. / Niedecker, S. / Isernia, M. / Ronco, V. et al. | 2018
-
CP2 - USING REAL WORLD DATA TO EXTRAPOLATE EVIDENCE FROM RANDOMIZED CLINICAL TRIALSWang, S.V. / Schneeweiss, S. / Gagne, J.J. / Evers, T. / Gerlinger, C. / Desai, R. / Najafzadeh, M. et al. | 2018
-
PCN386 - QUALITY OF LIFE OF CAREGIVERS OF CANCER PATIENTS BEFORE AND AFTER PATIENT ADMISSION TO AN INTENSIVE CARE UNITAl Rabayah, A.A. / Salmany, S. / Al Froukh, R. / AL Rayyan, M. / Al Najjar, B. / Nazer, L. et al. | 2018
-
PCP70 - REGENERATIVE MEDICINE: A PROPOSED CLASSIFICATION FOR HEOR BASED ON THERAPEUTIC STRATEGY AND TECHNOLOGY TYPEPurser, M. / Mladsi, D.M. et al. | 2018
-
PIH40 - THE HEALTH LITERACY OF IRANIAN PARENTS: A SURVEY IN TEHRAN CAPITAL CITYYousefi, N. / Peiravian, F. / Alavian, Y. et al. | 2018
-
PIH47 - SELF-MEDICATION PRACTICE IN PRIMARY DYSMENORRHEA AMONG MEDICAL AND PHARMACY STUDENTS IN UNAIZAH – KSA - A CROSS-SECTIONAL QUESTIONNAIRE STUDYAl-Rashidi, A. / Al-Subaie, S.A. / Farooqui, M. et al. | 2018
-
PIH14 - FACTORS ASSOCIATED WITH THE USE OF ANTIPYRETICS IN CHILDREN OF PARENTS IN A COHORT SAMPLE IN SAUDI ARABIAAlmogbel, Y. / AlQussiar, J. et al. | 2018
-
PIH27 - IRANIAN PARENTS' KNOWLEDGE ABOUT ANTIBIOTICSSharif, Z. / Yousefi, N. / Peiravian, F. / Alavian, Y. et al. | 2018
-
PHP218 - HOW HIGH CAN YOU GO? - THE IMPACT OF INDICATION EXPANSION AND MARKET COMPETITION ON DRUG PRICES IN THE EU5Radu, X. / Damera, V. / Martin, M. et al. | 2018
-
PHP201 - DEVELOPMENT OF MEDICATION SAFETY STANDARDS IN SELECTED HOSPITALS IN IRANIzadpanah, F. / Nikfar, S. / Bakhshi Imcheh, F. / Zargaran, M. et al. | 2018
-
PHP208 - PHYSICIANS' IMPROVEMENT SUGGESTIONS FOR ENTERAL NUTRTION CARE IN CHINA: A CROSS-SECTIONAL SURVEYSuo, S. / Ung, C.O. / Shi, H. / Chen, S. / Hu, H. et al. | 2018
-
PHP150 - GEOGRAPHICAL VARIABILITY IN THE UTILIZATION OF SERVICES AND PHARMACEUTICAL EXPENDITURE BY ADVANCED CHRONIC PATIENTSDíaz-Carnicero, J. / Uso-Talamantes, R. / Bertomeu-Izquierdo, L. / Trillo Mata, J.L. / Vivas, D. et al. | 2018
-
PHP153 - KEY STAKEHOLDERS PERCEPTIONS OF HEOR USAGE IN LEBANONMesmar, A. / Maskineh, C. / Becker, R.V. et al. | 2018
-
PHP146 - ANALYSES OF THE PERFORMANCE INDICATORS OF REHABILITATION AND CHRONIC INPATIENT CARE IN HUNGARY BETWEEN 1990 AND 2016Ágoston, I. / Endrei, D. / Molics, B. / Szarka, E. / Gyuró, M. / Komáromy, M. / Boncz, I. et al. | 2018
-
PHP133 - TOWARDS IMPLEMENTING MEDICATION THERAPY MANAGEMENT SERVICE IN MALAYSIA: PERCEPTIONS AND CHALLENGESAl-Tameemi, N.K. / Sarriff, A. et al. | 2018
-
PHP116 - TREND IN OPIOID USE FROM 2001 THROUGH 2013 AMONG ELDERLY US VETERANSDwibedi, N. / Rowneki, M. / Shen, C. / Helmer, D. / Sambamoorthi, U. et al. | 2018
-
PHP97 - NONADHERENCE TO TACROLIMUS IN ADULT LIVER AND KIDNEY TRANSPLANTATION IS ASSOCIATED WITH A HIGHER RISK OF EFFICACY FAILURE: REAL-WORLD EVIDENCE FROM ITALIAN ADMINISTRATIVE DATABASESVeronesi, C. / Biancone, L. / Burra, P. / De Simone, P. / Grandaliano, G. / Rigotti, P. / Tisone, G. / Perrone, V. / Degli Esposti, L. et al. | 2018
-
PHP80 - HOW CLASSIFICATION OF CELL AND GENE THERAPIES AS DRUGS, DEVICES OR PROCEDURES COULD HAVE SIGNIFICANT IMPLICATIONS FOR THEIR PRICING AND REIMBURSEMENT AND COMMERCIAL SUCCESSMacaulay, R. / Wang, G.D. / Rothwell, S. et al. | 2018
-
PHP65 - ANALYSIS OF ICER-ESTIMATED VALUE-BASED PRICES AND POTENTIAL DISCOUNTS FOR DRUGS IN THE UNITED STATESKloc, K. / Dusza, M. / Lach, S. / Sediri, Y. / Rémuzat, C. / Toumi, M. et al. | 2018
-
PHP58 - SPANISH THERAPEUTIC POSITIONING REPORTS: 6-YEAR UPDATE – INCREASING IN FREQUENCY BUT NOT RELEVANCE?Macaulay, R. / Fernandez Dacosta, R. et al. | 2018
-
PHP50 - PRICE REGULATION ORDINANCE IMPACT ON REIMBURSED PRICES FOR MOSTLY PRESCRIBED MEDICINES IN BOSNIA AND HERZEGOVINAČatić, T. / Jusufović, R. / Tabakovic, V. et al. | 2018
-
PHP21 - METHODOLOGY OF IDENTIFICATION OF RISK GROUPS UNDER PHARMACEUTICAL GUIDELINES IN A SPECIAL REGIME INSURER IN COLOMBIARomero, M. / Gallo, D. / Silva, E. et al. | 2018
-
PHP47 - EVALUATING PATIENTS', PHYSICIANS' AND PHARMACISTS' PERCEPTION REGARDING GENERIC MEDICINES IN GONDAR, NORTHWEST ETHIOPIAGebresillassie, B.M. et al. | 2018
-
PHP30 - THE CONTRIBUTION OF NEW PRODUCT ENTRY VS EXISTING PRODUCT INFLATION IN THE RISING COSTS OF PRESCRIPTION DRUGS IN THE UNITED STATESHernandez, I. / Good, C.B. / Cutler, D. / Gellad, W.F. / Parekh, N. / Shrank, W.H. et al. | 2018
-
PGI33 - URSODEOXYCHOLIC ACID TO GALLSTONE DISSOLUTION THERAPY IN ASYMPTOMATIC CHOLELITHIASIS PATIENTS: A SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETYSenna, K. / Santos, M. / Parreira, V. et al. | 2018
-
PGI23 - COST-EFFECTIVENESS ANALYSIS OF PARENTERAL METHOTREXATE FOR THE TREATMENT OF CROHN'S DISEASE IN THE CZECH REPUBLICMlcoch, T. / Hajickova, B. / Ornstová, E. / Chadimova, K. / Bartakova, J. / Dolezal, T. et al. | 2018
-
PDB127 - APPLICATION OF BEST WORST SCALING TO IMPROVE PATIENT-CENTERED TREATMENT DECISIONS IN DIABETIC PERIPHERAL NEUROPATHYAdams, A.S. / Prosser, L. / Altschuler, A. / Ma, L. / Wittenberg, E. et al. | 2018
-
PDB103 - FINANCIAL ACCESS TO HEALTH CARE USE IN DIABETICS WITH HIGH-DEDUCTIBLE HEALTH PLAN (HDHP)Yao, J. / Li, M.S. / Lu, K. et al. | 2018
-
PDB134 - CHARACTERISTICS OF US ADULTS WITH CONTROLLED AND UNCONTROLLED TYPE 2 DIABETESMorlock, A. / Dobrescu, R. et al. | 2018
-
PHP352 - SUCCESS FACTORS FOR THE IMPLEMENTATION OF MARKET ACCESS AGREEMENTS IN EMERGING MIDDLE-INCOME MARKETS IN PREPARATION FOR OUTCOMES BASED CONCEPTSBayard, J.K. / Gretsch, K. / Hallal, Z. / Stojkovic, N.S. / Strydom, J. et al. | 2018
-
PHP339 - MINIMALLY IMPORTANT DIFFERENCE (MID) OF EQ-5D-5L INDEX SCORE IN HONG KONG ADULTS POPULATION USING HONG KONG SCORING ALGORITHMWong, E.L. / Cheung, A.W. / Yau, P.S. / Wong, A.Y. / Xu, H. / Ramos Goñi, J.M. / Rivero-Arias, O. et al. | 2018
-
PHP336 - THE PRESCRIPTION COST ANALYSIS AS A TOOL TO INFORM HEALTHCARE RESOURCE ALLOCATION AND ACCESS TO PHARMACEUTICALS IN ENGLANDJohnson, K.I. / Jones, C. / Zabala Mancebo, J. et al. | 2018
-
PHP311 - UPTAKE OF JOINTLY PRODUCED EUNETHTA HEALTH TECHNOLOGY ASSESSMENTS: WHERE ARE WE NOW?Garrett, Z. et al. | 2018
-
PHP310 - COMPARISON OF THE HEALTH TECHNOLOGY ASSESSMENT OFFICES OF HUNGARY AND POLAND BASED ON OBJECTIVE CRITERIANemeth, B. / Krupa, D. / Staniak, A. / Józwiak-Hagymásy, J. / Vokó, Z. et al. | 2018
-
PHP300 - HEALTH TECHNOLOGY ASSESSMENT ROADMAP FOR UKRAINE - THE PERSPECTIVE OF STAKHOLDERS ON CURRENT STATUS AND FUTURE OPPORTUNITIESCsanádi, M. / Inotai, A. / Németh, B. / Oleshchuk, O. / Lebega, O. / Brodovskaya, A. / Piniazhko, O. / Kaló, Z. et al. | 2018
-
PHP273 - A REVIEW OF ISSUES AFFECTING THE EFFICIENCY OF DECISION MAKING IN THE NICE SINGLE TECHNOLOGY APPRAISAL PROCESSWalton, M.J. / O'Connor, J. / Carroll, C. / Biswas, M. / Claxton, L. / Hodgson, R. et al. | 2018
-
PHP259 - PHARMACOECONOMIC GUIDELINES RECOMMENDATION FOR TURKEY CONSIDERING REFERENCE COUNTRIESMihajlovic, J. / Yeğenoğlu, S. / Sozen Sahne, B. / Postma, M. et al. | 2018
-
PHP226 - VALUE-BASED PRICING WHEN THE VALUE DIFFERS BETWEEN INDICATIONS – WHAT IS THE GERMAN WAY?Witte, J. / Greiner, W. et al. | 2018
-
PDB96 - APPLYING MCDA FRAMEWORK IN PHARMACEUTICAL POLICY DECISION MAKING: A PILOT STUDY IN DIABETES MELLITUS TYPE 2Comellas, M. / Santiago, C. / Gasol, M. / Navarro, J. / Uso-Talamantes, R. / Fernandez, I. / Lizán, L. et al. | 2018
-
PDB49 - TYPE 2 DIABETES MELLITUS IN ALGERIA – A COST OF ILLNESS STUDYOulad abdallah, R. / Boukana, R. / Loumi, W. / Nebchi, E. / Mimene, A. et al. | 2018
-
PDB44 - THE HEALTH ECONOMIC VALUE OF SHORT-TERM CARDIOVASCULAR BENEFITS ASSOCIATED WITH SGLT-2I FROM CVD-REALWard, T. / Bennett, H. / McEwan, P. / Edmonds, C. / Kartman, B. / Fenici, P. / Thuresson, M. / Kosiborod, M. et al. | 2018
-
PDB3 - THE IMPACT OF GLYCATED HEMOGLOBIN CONTROL ON MORBIDITY AND SURVIVAL AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUSHammad, M.A. / Syed Sulaiman, S.A. / Qamar, M. / Shaikh, F.A. / Mohamed Noor, D.A. et al. | 2018
-
PCV138 - TREATMENT PATTERNS OF PATIENTS WITH VENOUS THROMBOEMBOLISM TREATED WITH ORAL ANTICOAGULANTS IN ENGLANDCarroll, R. / Lambrelli, D. / Donaldson, R. / Schultze, A. / Nordstrom, B. / Stynes, G. / Ramagopalan, S. / Alikhan, R. et al. | 2018
-
PCV121 - PERFORMANCE INDICATORS OF CARDIAC REHABILITATION IN HUNGARYEndrei, D. / Sebestyén, A. / Ágoston, I. / Csákvári, T. / Kovács, G. / Nogel, M. / Boncz, I. et al. | 2018
-
PCV126 - A COST-EFFECTIVENESS THRESHOLD BASED ON THE MARGINAL RETURNS OF CARDIOVASCULAR HOSPITAL SPENDINGvan Baal, P. / Perry-Duxbury, M. / Bakx, P. / Versteegh, M. / van Doorslaer, E. / Brouwer, W. et al. | 2018
-
PCV101 - HYPERTRIGLYCERIDEMIA AND RISK OF ALL-CAUSE MORTALITY AND MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) EVENTS IN CLINICAL PRACTICE: THE TG-REAL STUDYVeronesi, C. / Arca, M. / Borghi, C. / Colivicchi, F. / De Ferrari, G. / Desideri, G. / Pontremoli, R. / Temporelli, P. / Perrone, V. / Degli Esposti, L. et al. | 2018
-
PCV105 - POTENTIAL REDUCTION IN MORTALITY AND HOSPITALISATIONS WITH OPTIMAL USAGE OF SACUBITRIL/VALSARTAN THERAPY FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN IRELANDO'Brien, S. / Sweeney, C. / Carney, P. et al. | 2018
-
PCV94 - NUTILIS CLEAR® IN DYSPHAGIC ADULT STROKE PATIENTS WITH ASPIRATION OF 10–14 POINTS ON GUSS SCALEPelczarska, A. / Jakubczyk, M. / Niewada, M. / Lipka, I. et al. | 2018
-
PCV82 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN SINGAPOREDeclan, L. / Tang, Z.X. / Ng, C. / Tan, J. / Trueman, D. / Woodcock, F. / Cristino, J. et al. | 2018
-
PCV93 - COST-EFFECTIVENESS OF GUIDELINE ADHERENCE IN CORONARY PATIENTS: THE IMPACT OF THE METHODOLOGYDe Smedt, D. / Annemans, L. / Kotseva, K. / Wood, D. / De Backer, G. / Rydén, L. / De Bacquer, D. et al. | 2018
-
PCV79 - REAL-WORLD COST-EFFECTIVENESS OF RIVAROXABAN COMPARED WITH VITAMIN K ANTAGONISTS IN THE CONTEXT OF STROKE PREVENTION IN ATRIAL FIBRILLATION IN FRANCEBowrin, K. / Briere, J. / Millier, A. / Levy, P. / Clay, E. / Toumi, M. et al. | 2018
-
PCN243 - POST-LOE PRICING DYNAMICS IN ONCOLOGY: IMPACT OF MANDATORY PRICE DISCOUNTS ON LIST PRICES AND GENERIC UPTAKESeitlinger, J. / Flostrand, S. et al. | 2018
-
PCN265 - END OF LIFE CANCER CHEMOTHERAPY: A RETROSPECTIVE STUDY DURING INTENSIVE CARE UNIT (ICU) STAYReis Neto, J.P. / Busch, J.M. et al. | 2018
-
PCN271 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH BREAST CANCER IN SPAINCallejo-Velasco, D. / Gómez-Navarro, V. / Solozabal, M. / Planellas, L. / Carreño-Serra, A. / Á, Baltasar-Sanchez et al. | 2018
-
PCN229 - COMPARISON OF SICKNESS BENEFIT AND SICK LEAVE DURATION IN ONCOLOGY ACROSS COUNTRIESContente, M. / Singh, P. / Smela-Lipińska, B. / van Dijk, B. / François, C. et al. | 2018
-
PCN247 - TREATMENT PATTERNS IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (R/M SCCHN) POST PLATINUM-BASED THERAPY (PPBT) IN THE IMMUNO-ONCOLOGY (IO) ERARadtchenko, J. / Korytowsky, B. / Abraham, P. / Singh, P. / Feinberg, B.A. et al. | 2018
-
PCN202 - IMPACT OF COMORBID DEPRESSION ON RATES, COSTS, AND HEALTH CARE RESOURCE USE IN BREAST CANCER PATIENTSChung, J. / Merritt, N. / Kish, J. / Nabhan, C. / Feinberg, B.A. et al. | 2018
-
PCN219 - CHARACTERISTICS AND TREATMENT PATTERNS IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC HORMONE RECEPTOR POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE (HER2-) BREAST CANCER IN CLINICAL PRACTICE: RETROSPECTIVE ANALYSIS FROM LEEDS CANCER CENTRECheeseman, S. / Thompson, M. / Riaz, M. / Twelves, C. / Perren, T. / Ahat-Donker, N. / Sopwith, W. / Myland, M. / Lee, A. / Przybysz, R. et al. | 2018
-
PCN220 - END-OF-LIFE CARE IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDSLeeneman, B. / Franken, M. / Aarts, M.J. / van Akkooi, A.C. / van den Berkmortel, F.W. / van den Eertwegh, A.J. / de Groot, J.W. / Herbschleb, K.H. / van der Hoeven, K.J. / Hospers, G.A. et al. | 2018
-
PCN185 - COST-EFFECTIVENESS OF NIVOLUMAB IN SECOND-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA IN ADULTS AFTER FAILURE OF PRIOR PLATINUM-CONTAINING THERAPY IN GREECEBoukouvalas, S. / Diamantogiannis, F. / Basta, E. / Stephens, S. et al. | 2018
-
PCN162 - DENOSUMAB VERSUS BISPHOSPHONATES FOR THE TREATMENT OF BONE METASTASES FROM SOLID TUMORS: A SYSTEMATIC REVIEW OF ECONOMIC STUDIESMatuoka, J. / Kahn, J. / Secoli, S.R. et al. | 2018
-
PCN190 - COST-EFFECTIVENESS OF NIVOLUMAB + IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDSKlijn, S. / Van de Wetering, G. / Malcolm, B. / Dale, P. / Pompen, M. / Stevanovic, J. et al. | 2018
-
PCN156 - PHARMACOECONOMICS OF NIMOTUZUMAB IN PATIENTS WITH HEAD AND NECK CANCER IN CUBAPérez, L. / Collazo, M.M. / Iznaga, N. / García, A. et al. | 2018
-
PCN149 - COST-EFFECTIVENESS OF BRCA1/2 MUTATION PROFILING TO TARGET OLAPARIB USE IN PATIENTS WITH METASTATIC BREAST CANCER IN JAPANSaito, S. / Nakazawa, K. / Nagahashi, M. / Akazawa, K. et al. | 2018
-
PCN137 - THE ECONOMIC EVALUATION OF IMATINIB COMBINED WITH CHEMOTHERAPY FOR PEDIATRIC PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN CHINAWang, V.W. / Li, Z. et al. | 2018
-
PCN144 - COST-EFFECTIVENESS OF CABOZANTINIB FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AFTER FAILURE OF PRIOR THERAPY IN SOUTH KOREAKim, S. / Han, S. / Kim, H. / Suh, H.S. et al. | 2018
-
PCN109 - EVALUATION OF THE FACTORS AFFECTING THE COST OF PALLIATIVE CARE AT A UNIVERSITY HOSPITALSozmen, M.K. / Koç, E.M. / C.A.N., H. / Kaplan, Y.C. et al. | 2018
-
PCN68 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN ENGLANDHollmann, S. / Painter, C. / Hogan, A. / Wickstead, R.M. / Goyert, N. / Patel, S. / Slowley, A. / Jousseaume, E. / El Ouagari, K. / Zhang, J. et al. | 2018
-
PCN65 - LONG- TERM SURVIVAL AMONG PATIENTS WITH HIGH-GRADE GLIOMA TREATED WITH NIMOTUZUMABSanchez, L. / Lorenzo-Luaces, P. / Viada Gonzalez, C. et al. | 2018
-
PCN63 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING MATCHING-ADJUSTED INDIRECT COMPARISONS AND SIMULATED TREATMENT COMPARISONSMuresan, B. / Hu, Y. / Postma, M.J. / Ouwens, M.J. / Heeg, B. et al. | 2018
-
PCN32 - THE EFFECTIVENESS AND SAFETY OF SWITCHING FROM ORGINAL FILGRASTIM TO BIOSIMILAR FILGRASTIM IN PRIMARY PROPHYLAXIS OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA: A RETROSPECTIVE COHORT STUDYAl Rabayah, A.A. / Hammoudeh, S. / Mashni, O. / Hanoun, E. / Al Qasem, W. / AL momani, D. et al. | 2018
-
PCN26 - ASSESSING THE POTENTIAL VALUE OF AN INNOVATIVE ONCOLOGY THERAPY FROM THE HEALTH TECHNOLOGY ASSESSMENT (HTA) PERSPECTIVE: MARRYING CLINICAL VALUE FRAMEWORKS WITH ECONOMIC ASSESSMENT METHODOLOGYZheng, Y. / Lanitis, T. / Ambavane, A. / Proskorovsky, I. / Bharmal, M. / Phatak, H. et al. | 2018
-
PCN11 - GLOBAL LONGITUDINAL ASSESSMENT OF TREATMENT OUTCOMES IN SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (GLANCE-H&N) STUDYGruenwald, V. / Chirovsky, D. / Cheung, W. / Bertolini, F. / Ahn, M. / Yang, M. / de Castro, G. / Berrocal, A. / Sjoquist, K. / Kuyas, H. et al. | 2018
-
DB4 - COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN ADULT PATIENTS WITH INADEQUATELY CONTROLLED TYPE 1 DIABETES: A HEALTH ECONOMIC ANALYSIS USING 24-WEEK RESULTS FROM THE DEPICT-1 RANDOMISED CONTROLLED TRIALBennett, H. / McEwan, P. / Evans, M. / Tank, A. et al. | 2018
-
PCV25 - LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF STATIN INTOLERANT PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALYGazzi, L. / Fanelli, F. / Heiman, F. / Di Filippo, A. / Pegoraro, V. et al. | 2018
-
PCV47 - PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONSZyryanov, S. et al. | 2018
-
PCV59 - HEALTH INSURANCE COST OF ESSENTIAL (PRIMARY) HYPERTENSION IN HUNGARY: A NATIONWIDE, REAL-WORLD COST OF ILLNESS STUDYEndrei, D. / Sebestyén, A. / Gazsó, T. / Zemplényi, A. / Gratz, B. / Boncz, I. et al. | 2018
-
PCV56 - CLINICAL AND ECONOMIC BURDEN OF CARDIOVASCULAR DISEASE AND VALUE OF EVOLOCUMAB TREATMENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN SWEDENHaines, P. / Sorio-Vilela, F. / Sandelin, R. / Villa, G. et al. | 2018
-
PCP63 - DETERMINING THE OPTIMAL COST-EFFECTIVENESS CUTOFF FROM FIRST PRINCIPLES OF ECONOMICSPhelps, C.E. et al. | 2018
-
PCV19 - PATTERNS OF ANTICOAGULATION CONTROL AND CLINICAL OUTCOMES IN ATRIAL FIBRILLATION PATIENTS TREATED WITH VITAMIN K ANTAGONISTS: A REAL-WORLD STUDY USING POPULATION-BASED DATA AND GROUP-BASED TRAJECTORY MODELSGarcia-Sempere, A. / Santaana, Y. / Rodriguez-Bernal, C. / Sanfelix, G. / Peiro, S. et al. | 2018
-
PCV11 - MODELING CARDIOVASCULAR EVENT REDUCTION THROUGH LOW-DENSITY LIPOPROTEIN REDUCTION IN COST-EFFECTIVENESS ANALYSES: A META-REGRESSION APPROACHDi Tanna, G.L. / Villa, G. et al. | 2018
-
PCV1 - NERVOUS SYSTEM DRUGS AND RISK OF ISCHEMIC STROKE: A REAL WORLD DATA CASE-CONTROL STUDYGomez-Lumbreras, A. / Giner, M. / Marsal, J. / García-Sangenis, A. / Pera, H. / Morros, R. et al. | 2018
-
PCP61 - EVIDENCE-BASED VALUE OF PD-1 / PD-L1 INHIBITORS IN NSCLC: COMPARISON OF VALUE TO PRICEDoyle, J.J. / Wood, B. et al. | 2018
-
PCP53 - A DIAGNOSTIC FRAMEWORK TO EVALUATE REAL-WORLD DATA SOURCES FOR REAL-WORLD EVIDENCE GENERATIONDenysyk, L. / Doyle, J. / Sood, R. et al. | 2018
-
PCP55 - REVIEW AND RECOMMENDATIONS OF ENDPOINTS FOR REAL-WORLD STUDIES IN ONCOLOGYJulian, G.S. / Duva, A. / Santana, P. / Cavalcanti, H.E. / Ballalai, A.F. et al. | 2018
-
PCP56 - EARLY ACCESS PROGRAMS: RECOMMENDATIONS FOR REAL-WORLD DATA COLLECTIONStein, D. / Soni, M. et al. | 2018
-
PCP33 - COULD THE US ADMINISTRATION IMPOSE DRUG PRICE RAISES IN THE EUROPEAN UNION (EU)?Dabbous, M. / Rémuzat, C. / Dussart, C. / Toumi, M. et al. | 2018
-
PCP22 - KILL / REPLACE / REGULATE: MOLECULAR-LEVEL VIEW OF TREATING DISEASE, EMERGING SOLUTIONS AND IMPLICATIONS FOR THE FUTURE OF HEALTHCARESogokon, P. / Morrison, S. et al. | 2018
-
PCP18 - EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT: A MARKER OF HTA FAILURE?Pisarczyk, K. / Rémuzat, C. / Hajjeji, B. / Toumi, M. et al. | 2018
-
PCP5 - THE ECOLOGICAL AND SOCIAL COSTS AND BENEFITS OF INTERVENTIONS – USING THE PRODUCT CARBON FOOTPRINT IN VALUE ASSESSMENTMiltenburger, C. / Borgstrom, F. / Ortsater, G. et al. | 2018
-
PCP11 - ORGANISATIONAL MODELS AND OPPORTUNITIES FOR EFFICIENCY MEASURING IN HEALTH CAREAraja, D. et al. | 2018
-
PCP44 - IMPLICATIONS OF GENOME-DRIVEN ONCOLOGY ON EVIDENCE REQUIREMENTS FOR HEALTH TECHNOLOGY ASSESSMENTLeslie, I. et al. | 2018
-
PCN364 - EVALUATING PSYCHOMETRIC PROPERTIES OF UK EQ-5D-5L SCORING ALGORITHMS IN METASTATIC MERKEL CELL CARCINOMABharmal, M. / Hunger, M. / Schlichting, M. et al. | 2018
-
PCN365 - AN ASSESSMENT OF PATIENT REPORTED OUTCOME (PRO) CLINICAL TRIAL DATA REPORTING, SPECIFIC TO CHOLANGIOCARCINOMA (CCA)Bernarde, J. / Boxell, E. / Baldock, L. / Rylands, A.J. et al. | 2018
-
PCN304 - APPROPRIATE COMPARATOR IN GERMAN AMNOG BENEFIT ASSESSMENTS IN MELANOMA – A DYNAMIC SITUATIONItalia, N. / Kossow, S. / Claes, A. / Templin, C. / Kulp, W. et al. | 2018
-
PCN318 - CONDUCTING AND REPORTING INDIRECT TREATMENT COMPARISONS: A CRITICAL APPRAISAL OF ONCOLOGY TECHNOLOGY APPRAISALSLangham, J. / Langham, S. et al. | 2018
-
PCN290 - USE OF PCR AS A SURROGATE PRIMARY ENDPOINT IN DRUG PIVOTAL TRIALS IN NEOADJUVANT EARLY BREAST CANCER IN EU: A PERSPECTIVE FROM REGULATORS AND PAYERSFonseca, A.F. / Deplazes, S.N. et al. | 2018
-
HT7 - A REVIEW OF EFFICIENCY OPINIONS OF FRENCH 'HAUTE AUTORITE DE SANTE' (HAS) IN THE ONCOLOGY FIELDGalasso, A. / Diaz A, Medina / Cotté, F. / Gaudin, A. et al. | 2018
-
CN5 - COST-EFFECTIVENESS OF PEMBROLIZUMAB VERSUS STANDARD-OF-CARE CHEMOTHERAPIES FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE (≥50%) METASTATIC NON-SMALL CELL LUNG CANCER IN FRANCEChouaid, C. / Bensimon, L. / Clay, E. / Millier, A. / Lévy-Bachelot, L. / Huang, M. / Levy, P. et al. | 2018
-
CE3 - COST-EFFECTIVENESS OF DEMENTIA CARE MANAGEMENT ALONGSIDE A CLUSTER-RANDOMIZED CONTROLLED INTERVENTIONAL DELPHI TRIALMichalowsky, B. / Xie, F. / Kaczynski, A. / Hoffmann, W. et al. | 2018
-
AC4 - RETROSPECTIVE ANALYSIS OF INAPPROPRIATE MEDICATION PRESCRIPTION INDICATORS IN ELDERLY POPULATION IN ITALYGalimberti, F. / Casula, M. / Olmastroni, E. / Russo, V. / Piscitelli, A. / Orlando, V. / Menditto, E. / Tragni, E. et al. | 2018
-
AD4 - ARE PATIENT-REPORTED PERSISTENCE AND ADHERENCE TO TREATMENT FOR A CHRONIC DISEASE VALID OUTCOMES? AN EXAMPLE WITH OSTEOPOROSISSenay, A. / Perreault, S. / Delisle, J. / Morin, S.N. / Banica, A. / Laflamme, Y. / Leduc, S. / Mac-Thiong, J. / Ranger, P. / Rouleau, D. et al. | 2018
-
PCN322 - AN EXAMPLE OF RWE USED FOR HTA EVALUATION: ERLOTINIB RENEGOTIATION IN ITALYRecchia, A. / Gervasi, A. / Avitabile, A. / Greco, A. et al. | 2018
-
CN1 - VALIDATING SURVIVAL EXTRAPOLATIONS IN FIRST LINE TREATMENT OF RENAL CELL CARCINOMA USING LITERATURE-BASED CONDITIONAL SURVIVAL PROBABILITIESKlijn, S. / Hofstra, M. / Malcolm, B. / Johannesen, K.M. et al. | 2018
-
PDB137 - COMPARISON OF ORAL ANTIDIABETIC DRUGS AS ADD-ON TREATMENTS IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED ON METFORMIN: A NETWORK META-ANALYSISSitu, B. et al. | 2018
-
PGI52 - DECREASED WORK PRODUCTIVITY AND INCREASED HEALTHCARE RESOURCE UTILISATION (HRU) AMONG PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) – RESULTS FROM A REAL WORLD EVIDENCE STUDYKnight, A. / Balp, M. / Mckenna, S.J. / Przybysz, R. / Cai, J. / Brass, C. / Howe, T. / Rosen, D. / Gavaghan, M. / Vazquez, V.C. et al. | 2018
-
PIN20 - A COST-EFFECTIVENESS ANALYSIS OF THE INFLUENZA VACCINE IN ADULT PATIENTS WITH CANCERShields, G.E. / Cranmer, H. / Camacho, C. / Porter, J.K. et al. | 2018
-
PIN22 - A PAYER PERSPECTIVE OF THE HOSPITAL INPATIENT ADDITIONAL CARE COSTS OF ANTIMICROBIAL RESISTANCE IN FRANCE: A MATCHED CASE-CONTROL STUDYTouat, M. / Brun-Buisson, C. / Opatowski, M. / Cosker, K. / Guillemot, D. / Salomon, J. / Tuppin, P. / de Lagasnerie, G. / Watier, L. et al. | 2018
-
PIN12 - HOSPITALIZATIONS RELATED TO RESPIRATORY VIRAL INFECTIONS DURING THE 2017/18 SEASON IN THE VALENCIA REGION OF SPAINMira-Iglesias, A. / Baselga-Moreno, V. / López-Labrador, F.X. / Díez-Domingo, J. et al. | 2018
-
PIH51 - THE EFFECT OF EXERCISING ON SEXUAL FUNCTIONS IN POST-MENOPAUSAL WOMENNovák, E. / Oláh, A. / Vajda, R. / Csákvári, T. / Boncz, I. / Ferenczy, M. / Kiss, T. / Radics, L. / Pakai, A. et al. | 2018
-
PIH29 - DEVELOPMENT OF A DECISION AID PROTOTYPE FOR PARENTS CONSIDERING TUBE FEEDING FOR THEIR CHILDRENRivero, C. / Rodriguez, A. / Moreno, A. / Vives, I. / Layola, M. / Gabás-Rivera, C. / Aceituno, S. et al. | 2018
-
PIH34 - PROGRAM 75+ - FREE MEDICINES FOR THE ELDERLYPlisko, R. / Rutkowski, J. et al. | 2018
-
PIN5 - 10 YEARS OF HUMAN PAPILLOMAVIRUS SYSTEMATIC VACCINATION IN SPAIN: FORECASTING HEALTH OUTCOMES CONSIDERING AS04-HPV16/18 VACCINE EFFECTIVENESS DATAMorano, R. / Cambronero, Md / López Sanromá, M. et al. | 2018
-
PIH30 - ASSESSMENT OF TREATMENT PATTERN IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME (PCOS) IN A TERTIARY CARE HOSPITAL IN URBAN SETTINGKrishna Murthy, M. / Ravi, R. / Jose, S.A. / Pudi, C. / Koonisetty, K.S. / Minnikanti, S.S. et al. | 2018
-
PIH21 - BUDGET IMPACT OF A NEW INTRAUTERINE SYSTEM IN PORTUGALMaia-Lopes, S. / Pissarra, M. / André, S. et al. | 2018
-
PIH6 - DEVELOPMENT AND VALIDATION OF A SCREENING QUESTIONNAIRE TO DETECT HEAVY MENSTRUAL BLEEDING IN GYNAECOLOGY: THE SAMANTA QUESTIONNAIRERius, J. / Carrasco, M. / Pujol, P. / Catafal, G. / Perelló, J. / Calaf, J. et al. | 2018
-
PIH11 - ANTIEMETIC USE IN PREGNANCY AND THE RISK OF MAJOR CONGENITAL MALFORMATIONS: A POPULATION-BASED COHORT STUDYBérard, A. / Sheehy, O. / Gorgui, J. / Zhao, J. / Moura, C. / Bernatsky, S. et al. | 2018
-
PHP366 - DEVELOPMENT OF THE UNIFIED SYSTEM OF ASSESSMENT OF LEVELS OF EVIDENCE AND GRADES OF RECOMMENDATIONS FOR THE RUSSIAN FEDERATIONKhachatryan, G.R. / Fedyaeva, V. / Omelyanovskiy, V. / Avxentyeva, M. / Sukhorukikh, O. / Galeeva, Z. / Lukyantseva, D. et al. | 2018
-
PCV159 - THE IMPACT OF SUBSEQUENT CARDIOVASCULAR (CV) EVENTS ON HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH A PRIOR MYOCARDIAL INFARCTION (MI) - A SYSTEMATIC LITERATURE REVIEWGogna, S. / Cholasamudram, S. / Jindal, R. / Cristino, J. / Laires, P.A. et al. | 2018
-
PIN14 - BIOMEDICAL AND THERAPEUTIC PREDICTORS OF SURVIVAL TIME AND MORTALITY OF ADULT HIV/TB CO-INFECTIONS; A RETROSPECTIVE COHORT STUDYTadesse, N. / Fang, Y. et al. | 2018
-
PIN13 - THE INCIDENCE OF SURGICAL SITE INFECTION IN POLANDPrzekopinska, B. / Macioch, T. / Niewada, M. et al. | 2018
-
PIH38 - PREVALENCE OF PELVIC FLOOR DISORDERS AMONG WOMEN IN EASTERN REGION OF NEPALSubedi, L. / Regmi, M.C. et al. | 2018
-
PIH49 - KNOWLEDGE ABOUT MENSTRUAL HYGIENE – TOXIC SHOCK SYNDROMEKrizsics, V. / Váradyné Horváth, Á. / Oláh, A. / Csákvári, T. / Kozmann, K. / Boncz, I. / Radics, L. / Kis, T. / Pakai, A. et al. | 2018
-
PIH26 - PRACTICE TOWARD ANTIBIOTICS PREPARATION AMONG IRANIAN PARENTSPeiravian, F. / Sharif, Z. / Yousefi, N. / Alavian, Y. et al. | 2018
-
PHP357 - MAKING SENSE FROM ANTI-SENSE: LESSONS IN TRANSLATING EXPEDITED REGULATORY APPROVAL INTO REIMBURSEMENT AND COMMERCIAL SUCCESSBebee, T. / Macaulay, R. et al. | 2018
-
PIH15 - PREVALENCE OF DIAGNOSED UTERINE FIBROIDS AND ENDOMETRIOSIS IN THE US: DATA FROM A NATIONALLY REPRESENTATIVE POPULATION-BASED SURVEYCacheris, W.P. / Hunsche, E.G. et al. | 2018
-
PIH3 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION AFTER CAESAREAN SECTIONLeaper, D.J. / Holy, C.E. / Ghosh, E. / Chen, B.P. / Edmiston, C.E. et al. | 2018
-
PHP200 - A REVIEW OF ACHIEVEMENTS AND CHALLENGES OF IRAN'S HEALTH TRANSFORMATION PLANPeikanpour, M. / Esmaeli, S. / Yousefi, N. / Aryaeinezhad, A. / Rasekh, H.R. et al. | 2018
-
PHP147 - CHANGES IN THE NUMBER OF PHYSICIANS IN THE HEALTH CARE SYSTEM OF EUROPEAN COUNTRIESElmer, D. / Endrei, D. / Ágoston, I. / Horváth, L. / Molics, B. / Németh, N. / Horváthné Kívés, Z. / Boncz, I. et al. | 2018
-
PHP124 - INTRANSPARENT EXCEPTIONAL FUNDING IN FRANCE ENSURING CONTINUITY OF PATIENT ACCESS TO INNOVATIVE TREATMENTWeber, A. / Marre, C. / Leveque, D. / Toumi, M. et al. | 2018
-
PHP95 - THE STUDY OF DYNAMIC ADJUSTMENT MECHANISM OF MEDICAL SERVICE PRICE IN CHINALin, P. / Wang, Y. / Li, L. / Liu, B. et al. | 2018
-
PHP112 - DO PATIENTS KNOW ABOUT THEIR CHRONIC HEALTH PROBLEMS AND THE DRUGS THEY TAKE?Inoriza, J.M. / Cols, M. / Sanchez-Perez, I. / Ibern, P. / Coderch, J. / Carreras, M. et al. | 2018
-
PHP89 - CLASS CNN DRUGS IN ITALY: PURCHASE AND PRESCRIPTION BEHAVIOR IN ITALIAN HOSPITALSGallo, A. / Stanisic, S. / Neumann, U. / Berto, P. et al. | 2018
-
PHP84 - INVESTIGATING USAGE OF REFERENCE COUNTRIES FOR PRICING AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINES IN CEE COUNTRIESBenisheva Dimitrova, T. / Boncheva, E. / Cherneva, D. et al. | 2018
-
PHP94 - DOES THE ORPHAN DESIGNATION INCREASE THE CHANCES OF POSITIVE HTA OPINION IN FRANCE, GERMANY AND UK?Caban, A. / Tomassy, J. / Rémuzat, C. / Toumi, M. et al. | 2018
-
PHP68 - HOW REGULATORY PATHS FOR E-HEALTH SOLUTIONS COULD FURTHER IMPACT MARKET ACCESS IN THE UNITED STATES AND THE EUROPEAN UNIONKloc, K. / Lach, S. / Dusza, M. / Rémuzat, C. / Sediri, Y. / Palencia, R. / Abshagen, D. / Toumi, M. et al. | 2018
-
PHP64 - ALLOWABILITY OF OUTCOMES-BASED RISK-SHARING SCHEMES IN RUSSIA WITHIN CURRENT LEGISLATIVE HURDLESTolkushin, A. / Kokushkin, K. / Davydovskaya, M. / Ermolaeva, T. et al. | 2018
-
PHP45 - AN INITIAL ANALYSIS OF THE COST-BASED PRICING REVISIONS IN JAPANGillespie, E. / Campbell, P.R. / Halcovich, C. / Gaebler, J.A. et al. | 2018
-
PHP41 - IMPACT OF PRICE REGULATION ORDINANCE ON TOP 20 PRESCRIBED MEDICINES PRICES IN BOSNIA AND HERZEGOVINAČatić, T. / Jusufović, R. / Tabakovic, V. / Begovic, B. et al. | 2018
-
PHP27 - EFFECTIVENESS OF COMMUNITY-BASED INTERVENTIONS FOR THE PREVENTION AND TREATMENT OF MENTAL HEALTH PROBLEMS AND MENTAL DISORDERS IN THE GENERAL POPULATION: SYSTEMATIC REVIEWPerez, D.M. / Mejia, L.C. / Sánchez, M.R. / Garzón-Orjuela, N. / Eslava-Schmalbach, J. et al. | 2018
-
PHP22 - IS THE EUROPEAN BIOSIMILAR MEDICINES MARKET BECOMING UNSUSTAINABLE? AN EXPLORATION OF THE COMBINED IMPACT OF COMPETITION, INTERCHANGEABILITY, PROCUREMENT, AND PRICINGTeale, C.W. / Sogokon, P. / Panciera, D. et al. | 2018
-
PGI27 - THERAPEUTIC STRATEGIES UTILIZATION AND RESOURCES CONSUMPTION IN PATIENTS AFFECTED BY CROHN DISEASE (CD) OR ULCERATIVE COLITIS (UC) IN AN ITALIAN REAL-WORLD SETTING, VENETO REGIONPerrone, V. / Sangiorgi, D. / Alessandrini, D. / Polini, M. / Andretta, M. / Degli Esposti, L. et al. | 2018
-
PDB121 - QUALITY OF LIFE AND UTILITY VALUES FOR COST-EFFECTIVENESS MODELING IN JAPANESE PATIENTS WITH TYPE 2 DIABETESCrawford, B. / Ishii, H. / Takamura, H. / Nishioka, Y. / Langer, J. / Watanabe, M. / KIM, H.R. et al. | 2018
-
PDB120 - EVALUATION OF HEALTH STATUS OF TYPE 2 DIABETES OUTPATIENTS RECEIVING CARE IN A TERTIARY HOSPITAL IN NIGERIAAdibe, M. et al. | 2018
-
PDB124 - PERSONALIZED DIABETES MANAGEMENT: WHAT DO PATIENTS WITH DIABETES MELLITUS PREFER?Mühlbacher, A.C. / Juhnke, C. / Sadler, A. et al. | 2018
-
PHP314 - THE RISE OF NICE ADVICE ON THE USE OF PHARMACEUTICALS, MEDICAL DEVICES AND DIGITAL HEALTH CARE IN THE NHSStevenson, A. / Ling, C. / Unsworth, H. et al. | 2018
-
PHP301 - THE TIME IS NOW FOR EUROPEAN HTA: HOW WILL THE EVOLUTION OF EUROPEAN HTA IMPACT ACCESS TO INNOVATIVE MEDICINES?Laisné, E. / Allen, N. / Kolotourou, K. / Sattler-Ermacora, P. / Grosvenor, A. et al. | 2018
-
PHP289 - AN EXAMINATION OF DELAYS DURING NICE TECHNOLOGY APPRAISAL REVIEWSAmbrose, S. / Naci, H. / Chesters, C. / Osipenko, L. / Mossialos, E. et al. | 2018
-
PHP269 - DESIGN AND EVALUATION OF MALAYSIAN MODEL OF PHARMACEUTICAL PICTOGRAMSTumkur, A. / Kwan, S. / Chee, J. / Teoh, H. / Ingle, P. / Molugulu, N. et al. | 2018
-
PHP266 - MANAGED ACCESS PROGRAMS: A FIRST STEP FOR UK HTA?Pandolfo, R. / Britt, R. / Oxborough, R.P. et al. | 2018
-
PHP260 - A EUROPEAN ANALYSIS OF FIXED DOSE COMBINATIONS PRICE SETTINGVialard, L. / Beillat, M. / Niang, H. / Papadatos, A. et al. | 2018
-
PHP280 - IS THERE A REASON TO ARGUE FOR HIGHER DECISION-MAKING EFFICIENCY WITH SINATS?Ferreira, C. / Andreozzi, V. / Vandewalle, B. / Félix, J. / Félix, A.R. et al. | 2018
-
PHP263 - COST EFFECTIVENESS AND COST UTILITY ANALYSIS STUDIES OF FIXED DOSE COMBINATIONS – A STUDY BASED ON PUBMED DATABASEDharmagadda, S. / Bhat, B. / Udupa, N. et al. | 2018
-
PHP247 - RISK-BASED CONTRACTING AND U.S. INSURERS: PAYER WILLINGNESS TO PARTICIPATE AND PREFERRED METRICS IN CHRONIC INDICATIONSMoore, R. / Lewis, C. et al. | 2018
-
PHP239 - THE INTRODUCTION AND IMPLICATIONS OF THE COST-CONTAINMENT MEASURE 'THE SLUICE' FOR EXPENSIVE INNOVATIVE DRUGS IN THE NETHERLANDSTrip, A.M. / van Steen, C. / Hensen, M. et al. | 2018
-
PHP224 - TEMPORARY ACCESS STRUCTURES FOR INNOVATIVE, HIGH-VALUE THERAPIES: COMPARISON OF MODELS AND CONSEQUENT REIMBURSEMENT TIMELINESWeston, A. / El Ghannam, M. et al. | 2018
-
PDB57 - TRENDS IN USE OF DRUGS FOR DIABETES TREATMENT IN SLOVAKIA: REVIEW OF CONSUMPTION DATA FROM 2007 TILL 2017Didič, R. / Cmorej, P. / Babela, R. et al. | 2018
-
PDB54 - ESTIMATED EVENTS AVOIDED AND COST OFFSETS ASSOCIATED WITH USING CANAGLIFLOZIN TO TREAT PATIENTS WITH TYPE TWO DIABETES MELLITUS (T2DM) WITH OR AT HIGH RISK OF DEVELOPING CARDIOVASCULAR DISEASE (CVD) IN ENGLANDGarcia Sanchez, J.J. / Willis, M. / Nilsson, A. / Ericson, O. / Ball, P. / Dunlop, W. et al. | 2018
-
PDB10 - MACROVASCULAR AND MICROVASCULAR COMPLICATIONS OF TYPE 2 DIABETES MELLITUS AND ITS ASSOCIATED FREQUENCY OF HOSPITAL ADMISSIONKeni, R. / Dhalla, R. et al. | 2018
-
PDB39 - EMPAGLIFLOZIN FOR PATIENTS IN THE NETHERLANDS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE: A BUDGET IMPACT MODELVoorhaar, M. / Nurkanovic, L. / Ustyugova, A.V. / Dvortsin, E. / Postma, M.J. et al. | 2018
-
PDB4 - THE EFFECT OF STATINS USAGE ON DIABETIC EYE COMPLICATIONSHammad, M.A. / Syed Sulaiman, S.A. / Mohamed Noor, D.A. et al. | 2018
-
PDB34 - CHARACTERIZATION OF THE RISK OF DEVELOPING DIABETES MELLITUS THROUGH THE USE OF THE FINDRISC SCALE IN A VOLUNTARY INSURANCE IN COLOMBIARomero, M. / Romero, Y. / Molano, M. / Useche, L. et al. | 2018
-
PCV146 - SYSTEMATIC LITERATURE REVIEW OF UTILITY DECREMENTS ASSOCIATED WITH THE NON-FATAL MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)Jindal, R. / Natani, H. / Gogna, S. / Yenamandra, J. / Laires, P.A. / Cristino, J. et al. | 2018
-
PCV148 - A SYSTEMATIC LITERATURE REVIEW ON HEALTH STATE UTILITIES ASSOCIATED WITH NON-FATAL STROKELaires, P.A. / Natani, H. / Cholasamudram, S. / Gupta, S. / Jindal, R. / Cristino, J. et al. | 2018
-
PCV104 - BETA-BLOCKERS, ANGIOTENSIN II, AND ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN PATIENTS WITH HEART FAILURE. DIFFERENCES IN PRESCRIPTION BY GENDER, SOCIOECONOMIC STATUS AND COMORBIDITY AFTER A FIRST HOSPITALIZATION FOR HEART FAILUREGarmendia, I. / Millan, E. / Trujillo, T.G. / Aizpuru, F. / Librero, J. / Mateos, M. / Ogueta, M. / Etxagibel, A. / Apiñaniz, A. / Samper, R. et al. | 2018
-
PCV106 - EVALUATION OF PRICES AND SALES VOLUME OF CARDIO-VASCULAR MEDICINES IN COMMUNITY PHARMACIESKazaryan, I. / Sevikyan, A. et al. | 2018
-
PCN240 - ALL-COMERS VS. BIOMARKER BASED PATIENT SELECTION FOR BIOTHERAPIES IN ONCOLOGY: IMPACT ON DRUG DEVELOPMENT AND MARKET ACCESSMassetti, M. / Leleu, H. / Vimont, A. / Antier, C. / Blachier, M. et al. | 2018
-
PCN276 - MANAGED ACCESS AGREEMENTS UNDER THE CANCER DRUGS FUND (CDF): KEY METRICS AND DRIVERSAdler, B. / Privolnev, Y. et al. | 2018
-
PCN254 - TRENDS IN BRCA TESTING OVER TIME AND SOCIOECONOMIC DEPRIVATIONMartin, A. / Pedra, G.G. / Downing, J. / Collins, B. / Godman, B. / Alfirevic, A. / Pirmohamed, M. / Greenhalgh, K.L. et al. | 2018
-
PCN259 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH MELANOMA CANCER IN SPAINBarrull, C. / Á, Baltasar-Sanchez / Callejo-Velasco, D. / Gómez-Navarro, V. / Canal-Díaz, N. / Solozabal, M. et al. | 2018
-
PCN256 - INDICATION-SPECIFIC PRICING IN ONCOLOGY: HOW WILL U.S. PAYERS DETERMINE VALUE AMID THIS GROWING TREND?Moore, R. / Lewis, C. et al. | 2018
-
PCN246 - EVOLUTION OF ONCOLYTICS CONSUMPTION IN PORTUGAL OVER TEN YEARSRamos, C. / Moreira, A. / Furtado, C. / Alves da Costa, F. et al. | 2018